let gColumns = [
    { title: "Author(s)"},  // 0
    { title: "Year"},   // 1
    { title: "Title"}, // 2
    { // 3
        title: "Link",
        "render": function (data, type, row, meta) {
            data = '<a href="' + data + '">' + data + '</a>';
            return data;
        }
    },
    { title: "Impacted Drug"},  // 4
    { title: "Gene"},   // 5
    { title: "Staging"},    // 6
    { title: "Therapeutic Field"},  // 7
    { title: "Adverse effect"}, // 8
    { title: "Polymorphism"}    //9
];

let gData = [
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","5-fluorouracil","DPD ","pre/post","Oncology","Myelosuppression, central neurotoxicity, and diarhea","DPYD c.1905+1G>A rs3918290 :  DPYD c.1679T>G  rs55886062 :  DPYD c.2846A>T rs67376798 : DPYD c.2579delA rs746991079 : DPYD c.1129-5923C>G  rs75017182"],
    ["Gross, E., et al. ",2008,"Strong association of common dihydropyrimidine dehydrogenase gene polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004003","5-Fluorouracil","DPYD","pre/post","Oncology","Neutropenia, thrombopenia, mucositis, diarrhea, nausea and vomiting, neurotoxicity, cardiac toxicity, alopecia and hand-foot-syndrome ","c.496A>G (p.Met166Val)"],
    ["Meulendijks, D., et al.",2015,"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.","https://www.ncbi.nlm.nih.gov/pubmed/26603945","5-fluorouracil","DPYD","pre/post","Oncology","Myelosuppression, central neurotoxicity, and diarhea","DPYD c.1679T>G :  DPYD c.1236G>A/HapB3"],
    ["Van Kuilenburg, A. ",2004,"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","http://www.ejcancer.com/article/S0959-8049(03)01069-4/fulltext","5-fluorouracil","DPYD ","pre/post","Oncology","Myelosuppression, central neurotoxicity and diarrhea","DPD IVS14+1G>A mutation"],
    ["Vujkovic, M., et al.",2015,"Association between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621538/","6 mercaptopurine","TPMT:MTHFR:MTR","pre/post","Oncology","Risk of relapse after pediatric ALL treatment ","rs2842947:rs1801131:rs1801133:rs10925235:rs1805087"],
    ["Coenen, M., et al.",2015,"Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease","http://www.gastrojournal.org/article/S0016-5085(15)00818-5/fulltext","6-mercaptopurine","TPMT","pre/post","Gastroenterology","Myelosuppression and liver toxicity","TPMT*2 238G>C rs1800462 :  TPMT*3A 460G>A rs1800460 :  TPMT*3A  719A>G  rs1142345 : TPMT*3C rs1142345"],
    ["Eichelbaum, M., et al.",2005,"Pharmacogenetics and individualized drug therapy","http://www.annualreviews.org/doi/pdf/10.1146/annurev.med.56.082103.104724","6-mercaptopurine","TPMT","pre/post","Oncology","Severe and life threatening hematopoietic toxicity","TPMT*2:TPMT*3A:TPMT*3C"],
    ["Ogungbenro, K., et al.",2015,"Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500328/","6-Mercaptopurine","TPMT ","pre/post","Oncology","Myelosuppression ","TMPT*1/*2 : TMPT*1/*3A :  TMPT*1/*3B :  TMPT*1/*3C :  TMPT*1/*4 :  TMPT*3A/*3A : TMPT*3A/*3A :  TMPT*3C/*3A : TMPT*3C/*4 : TMPT*3C/*2 :  TMPT*3A/*4"],
    ["Pirmohamed, M. ",2010,"Pharmacogenetics of adverse drug reactions ","https://www.researchgate.net/profile/Munir_Pirmohamed/publication/40697565_Pharmacogenetics_of_Idiosyncratic_Adverse_Drug_Reactions/links/09e4150fd81a89a128000000.pdf","6-Mercaptopurine","Thiopurine S-methyltransferase","pre/post","Oncology","Thiopurine S-methyltransferase was implicated in 6-MP hematological toxicity","*1/*3C"],
    ["Krasowski, M. ",2015,"Current Diagnosis & Treatment : Family Medicine Chapter 49: Pharmacogenomics","http://accessmedicine.mhmedical.com/content.aspx?bookid=1415&sectionid=77060360","6-mercaptopurine","TPMT","pre/post","Rheumatology ","Hematopoietic toxicity","TMPT genotype v/v : TMPT genotype wt/v : TPMT*2 : TPMT*3A : TPMT*3C"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","6-mercaptopurine and azathioprine","TPMT","pre/post","Oncology","Bone marrow toxicity, myelosuppression","TPMT*2 : TPMT*3A : TPMT*3C"],
    ["Wan Rosalina, W., et al.",2011,"Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukemia treated with 6-mercaptopurine ","http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2710.2011.01272.x/full","6-Merceptopurine","ITPA 94C>A","pre/post","Oncology ","Patients with ALL who had the ITPA 94A allel, versus the 94C allele, were more likely to develop fever and liver toxicity when treated with 6-MP. ","ITPA 94C"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Abacavir","HLA-B","pre","Infectious Disease","DRESS syndrome","HLA-B*5701"],
    ["Krasowski, M. ",2015,"Current Diagnosis & Treatment : Family Medicine Chapter 49: Pharmacogenomics","http://accessmedicine.mhmedical.com/content.aspx?bookid=1415&sectionid=77060359","Abacavir","HLA-B","pre","Infectious Disease"," DRESS syndrome ","HLA-B*5701"],
    ["Asensi, V., et al.",2015,"Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=nevirapine+side+effect+pharmacogenetic","Abacavir","HLAB","pre/post","Infectious Disease","Abacavir-associated hypersensitivity - due to HLAB*5701polymorphism in HIV patients receivig abacavir","HLAB*5701 (SNPs 2395029)"],
    ["Hetherington, S., et al.",2002,"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","http://www.sciencedirect.com/science/article/pii/S0140673602081588","Abacavir","HLA-B","pre/post","Infectious Disease","HLA-B27 was associated with abacavir hypersensitivity reactions. ","HLA-B27"],
    ["Pirmohamed, M. ",2010,"Pharmacogenetics of adverse drug reactions ","https://www.researchgate.net/profile/Munir_Pirmohamed/publication/40697565_Pharmacogenetics_of_Idiosyncratic_Adverse_Drug_Reactions/links/09e4150fd81a89a128000000.pdf","Abacavir","HLA-B","pre/post","Infectious Disease","HLA-B*571 is implicated in abacavir hypersensitivity","HLA-B*5701"],
    ["Yang, L., et al. ",2009,"Harvesting Candidate Genes Responsible for Serious Adverse Drug Reactions from a Chemical-Protein Interactome","http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1000441","Abacavir","MHC I","pre/post","Infectious Disease","Patients with the MHC I B*5701 gene polymorphism were more likely to have abacavir-induced hypersensitivity ","MHC-I B*5701"],
    ["Caudle, K.E., et al.",2014,"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206662/","Abacavir","HLA-B","pre/post","Infectious Disease","Induced hypersensitivity reaction","HLA-B*57:01"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","abacavir","HLA-B","peri","Infectious Disease","AHS abacavir hypersensitivity syndrome","HLA-B*57:01"],
    ["Mahmoudpour, S.H., et al. ",2013,"Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis.","https://www.ncbi.nlm.nih.gov/pubmed/23394388","ACE inhibitors","XPNPEP2","pre/post","Cardiology","ACEI-induced angioedema-  due to administration of ACEinhibitor in patients with polymorphism in gene region XPNPEP2.","rs4646994"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Allopurinol","HLA-B","pre","Rheumatology","Steven Johnson Syndrome, toxic epidermal necrolysis","HLA-B*5801"],
    ["Caudle, K.E., et al.",2014,"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206662/","Allopurinol","HLA-B","pre/post","Rheumatology","Induced severe cutaneous adverse reactions","HLA-B*58:01"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Allopurinol","HLA-B","peri","Rheumatology","DRESS, MPE, SJS/TEN","HLA-B*58:01"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Aminopenicillin","HLA-A","pre/post","Infectious Disease","delayed-type hypersensitivity reaction","HLA-A2 "],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Aminopenicillin","HLA-DR","pre/post","Infectious Disease","delayed-type hypersensitivity reaction","HLA-DRW52 "],
    ["Daly, A., et al.",2013,"Pharmacogenomics of adverse drug reactions","https://genomemedicine.biomedcentral.com/articles/10.1186/gm409","Amiodarone","NOS1AP ","pre/post","Cardiology","Drug nduced QT prolongation","single SNP (rs10800397)"],
    ["Hicks, J.K., et al.",2013,"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226/","Amitriptyline","CYP2D6 : CYP2C19","pre","Psychiatry","Coma, respiratory depression, tachycardia, QRS prolongation, decreased cardiac contractility , decreased GI motility, torsades de pointes","CYP2D6*1:  CYP2D6*2 : CYP2D6*3 : CYP2D6*4 : CYP2D6*5 : CYP2D6*6 :  CYP2D6*9 : CYP2D6*10 :  CYP2D6*1XN : CYP2D6*2XN : CYP2C19*1 : CYP2C19*2 : CYP2C19*3 : CYP2C19*17 "],
    ["Parikh, S., et al.",2007,"Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa","https://www.researchgate.net/publication/6446364_Amodiaquine_Metabolism_is_Impaired_by_Common_Polymorphisms_in_CYP2C8_Implications_for_Malaria_Treatment_in_Africa","Amodiaquine","CYP2C8","pre/post","Infectious Disease","abdominal pain - seen in both homozygotes and heterozygotes for CYP2C8*2 when amodiaquine is administered along with the polymosphism. Amodiaquineassociated toxicity- due to higher Km and lower intrinsic clearance by CYP2C8*2 polymorphism; markedly decreased activity of CYP enzyme - the effects of reduced metabolism of the amodiaquine are most proNoounced in CYP2C8*3 polymorphism.","CYP2C8*2:CYP2C8*3"],
    ["Roederer, M.W., et al.",2011,"Can pharmacogenomics improve malaria drug policy?","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209725/","Amodiaquine","CYP2C8","pre/post","Infectious Disease","Hepatotoxicity and agranulocitosis - If decreased function of the CYP2C8 gene. *2 and CYP2C8*3 have shown to cause a decreased metabolizing activity. Abdominal pain - when amodiaquine is given with CYP2C8*2 genotype. ","CYP2C8*2:CYP2C8*3"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Amoxicillin-clavulanate","HLA-A","pre/post","Infectious Disease","drug-induced liver injury","HLA-A*0201"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Amoxicillin-clavulanate","HLA-DRB :  HLA-DQB","pre/post","Infectious Disease","drug-induced liver injury","DRB1*1501:  DQB1*0602"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Amoxicillin-clavulanate","HLA-A: HLA-B: HLA-DRB1-HLA-DQB1","peri","Infectious Disease","DILI drug-induced liver injury","HLA-A*02:01,  HLA-A*30:02,  HLA-B*18:01,  DRB1*15:01-DQB1*0602 haplotype"],
    ["Chalasani, N., et al.",2010,"Risk Factors for Idiosyncratic Drug-Induced Liver Injury","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157241/","Amoxicillin/clavulanic acid","HLA B1:  HLA-DRB5 : HLA-DQB1","pre","Infectious Disease","Drug induced hepatotoxicity","HLA B1*1501:  HLA-DRB5*0101 : HLA-DQB1*0602"],
    ["Gervasini, G., et al.",2017,"Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/27747906","Anastrozole","ABCB1 ","pre/post","Oncology","Arthrialgia ","ABCB1 2677?TT"],
    ["Gervasini, G., et al.",2017,"Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/27747906","Anastrozole","CYP19A1 ","pre/post","Oncology","Arthrialgia and cancer recurrence in our patients."," CYP19A1 rs1008805 GG"],
    ["Vilaseca, M., et al. ",2000,"Anti-Epileptic drug treatment in children: Hyperhomocysteinaemia, B-Vitamins and the 677C?T Mutation of the Methylenetetrahydrofolate Reductase Gene","http://www.sciencedirect.com/science/article/pii/S1090379800903799","Anti-Epileptic drugs","MTHFR 677 C?T","pre/post","Neurology","Total homocysteine concentrations were significantly increased (p<0.05) and folate and vitamin B6levels were significantly decreased (p<0.01) in the children taking anti-epileptic drugs","MTHFR 677 C?T"],
    ["Feng, F.M., et al.",2014,"Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury","http://www.funpecrp.com.br/gmr/year2014/vol13-4/pdf/gmr4116.pdf","anti-TB chemotherapy","NAT2 : CYP2E1 : GSTM1 : GSTT1","pre/post","Oncology","anti-tuberculosis drug-induced hepatic injury (ADIH)","NAT2 : CYP2E1 : GSTM1 : GSTT1"],
    ["Bertilsson, I., et Al.",1997,"Pharmacogenetics of antidepressants: clinical aspects ","http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.1997.tb05954.x/full","Antidepressants","CYP2D6","pre/post","Psychiatry","Altered bioavaliability with increased side effect risk in slow metabolizers, in particularly higher drug doses in the body with increased risk of toxicity leading to death. ","CYP2D6 slow metabolizers"],
    ["Kircheiner, J., et al. ",2001,"CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants ","http://onlinelibrary.wiley.com/doi/10.1034/j.1600-0447.2001.00299.x/full","Antidepressants","CYP2D6:CYP2C19","pre/post","Psychiatry","For the tricyclic antidepressants, dose reductions around 50% were generally recommended for poor metabolizers of substrates of CYP2D6 or CYP2C19","CYP2D6:CYP2C19 poor metabolizers"],
    ["Eum, S., et al.",2016,"Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067149/","Aripiprazole","CYP2D6","pre/post","Psychiatry ","Increased mortality in elderly patients with psychosis caused by dementia, suicidal thoughts and behavior in children and young adults, neuroleptic malignant syndrome, and tardive dyskinesia. ","CYP2D6*1 : CYP2D6*2 : CYP2D6*33 : CYP2D6*35 : CYP2D6*9: CYP2D6*10 :  CYP2D6*17 : CYP2D6*29 : CYP2D6*36 : CYP2D6*41 : CYP2D6*4 :CYP2D6*3 : CYP2D6*5-8 : CYP2D6*11-16 : CYP2D6*19-21: CYP2D6*38 : CYP2D6*40 :  CYP2D6*42. CYP2D6*5 CYPD26*2XN "],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Aspirin","HLA-DRB :  HLA-DQB","pre/post","Cardiology ","Urticaria; severe cutaneous adverse drug reaction ","HLA-DRB1*1302: HLA-DQB1*0609"],
    ["Asensi, V., et al.",2015,"Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=nevirapine+side+effect+pharmacogenetic","Atazanavir","UGT1A1:ABCD1","pre/post","Infectious Disease","Enhance unconjugated hyperbilirubinemia and jaundice- due to modified plasma levels of atazanavir by UGT1A1*28 and ABCB1 (MDR1) 3435C > T SNPs ","UGT1A1*28 and ABCB1MDR1 3435C>T SNPs"],
    ["Turatti, L., et al.",2012,"Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.","https://www.ncbi.nlm.nih.gov/pubmed/22050734","Atazanavir","UGT1A1","pre/post","Infectious Disease","higher risk of severe hyperbilirubinemia - due to UGT1A1 polymorphism and the use of atezanavir. Uridine diphosphate-glucuroNosyltransferase is the enzyme in charge of thehepatic conjugation of billirubin and therefore its variations can affect the bilirubin concentration. ","UGT1A1*28, rs8175347"],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Atomoxetine","CYP2D6","pre/post","Psychiatry","Increased plasma concentration of Atomoxetine when given along with genetic polymorphism of CYP2D6 poor metabolizers. Dose adjustment is recommended in these patients. ","CYP2D6 poor metabolizers"],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Atorvastatin","CYP2D6","pre/post","Cardiology","Higher LDL cholesterol levels due to decreased efficacy","CYP3A5*1 c.6986A>G rs776746"],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Atorvastatin","POR","pre/post","Cardiology","Higher total and LDL cholesterol levels","POR*28"],
    ["Eichelbaum, M., et al.",2005,"Pharmacogenetics and individualized drug therapy","http://www.annualreviews.org/doi/pdf/10.1146/annurev.med.56.082103.104724","Azathioprine","TPMT","peri","Oncology","Severe and life threatening hematopoietic toxicity","TPMT*2:TPMT*3A:TPMT*3C"],
    ["Pirmohamed, M. ",2010,"Pharmacogenetics of adverse drug reactions ","https://www.researchgate.net/profile/Munir_Pirmohamed/publication/40697565_Pharmacogenetics_of_Idiosyncratic_Adverse_Drug_Reactions/links/09e4150fd81a89a128000000.pdf","Azathioprine","Thiopurine S-methyltransferase","pre/post","Rheumatology","Thiopurine S-methyltransferase was implicated in azathiprine hematological toxicity","heterozygous Non-functional TPMT alleles"],
    ["Schwab, M., et al. ",2002,"Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism","http://journals.lww.com/jpharmacogenetics/Abstract/2002/08000/Azathioprine_therapy_and_adverse_drug_reactions_in.3.aspx","Azathioprine","TMPT","pre/post","Rheumatology","Patients with polymorphisms in TMPT had increased risk of pancytopenia as a side effect of azathioprine, however GI side effects were not associated with this polymorphism ","TMTP *3A, *3C, *2"],
    ["Liu, Y.P., et al.",2015,"Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669175/","Azathioprine","TPMT","pre/post","Rheumatology ","Bone marrow toxicity and gastric intolerance","TPMT *3A, TPMT *3B and TPMT *3C"],
    ["Marinaki, A., et al. ",2004,"Adverse drug reactions to azathioprine therapy are associated in the gene encoding inosine triphosphate pyrophosphatase (ITPase) ","http://journals.lww.com/jpharmacogenetics/Abstract/2004/03000/Adverse_drug_reactions_to_azathioprine_therapy_are.6.aspx","Azathioprine","ITPA","pre/post","Rheumatology ","Polymorphism in ITPA leads to azothioprine intolerance including flu-like symptoms, rash and pancreatitis ","ITPA 94C"],
    ["Marinaki, A., et al.",2004,"Adverse drug reactions to azathioprine therapy are associated in the gene encoding inosine triphosphate pyrophosphatase (ITPase) ","http://journals.lww.com/jpharmacogenetics/Abstract/2004/03000/Adverse_drug_reactions_to_azathioprine_therapy_are.6.aspx","Azathioprine","ITPA","pre/post","Rheumatology ","Polymorphism in ITPA leads to azothioprine intolerance including flu-like symptoms, rash and pancreatitis ","ITPA 94C"],
    ["Goey, A., et al.",2016,"UGT genotyping in beliNostat dosing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775324/","Belinostat","UGT1A1 ","pre/post","Oncology","Hyperbillirubinemia, neutropenia, and thrombocytopenia","UGT1A1*28 rs8175347: UGT1A1*60 rs4124874 : UGT1A1*93 rs10929302"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Bicalutamide","ABCG2","pre/post","Oncology","Hepatoxicity and interstitial pneumonitis","ABCG2 c.421C>A  rs2231142"],
    ["Zabriskie, M.S., et al.",2014,"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160372/","Bosutinib","BCR-ABL1","pre/post","Oncology","Relapse of disease- Mutations in BCR-ABL1 may confer resistance and treatment failure leading to disease progression. T315I mutants are also found to confer high-level resistance to Tyrosine Kinase Inhibitors.","BCR-ABL1:M244, G250, Q252, Y253, E255, V299, F311, T315, F317, M351, F359, and H396:T315I"],
    ["Ishigooka J., et al.",2017,"Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.","https://www.ncbi.nlm.nih.gov/pubmed/?term=Brexpiprazole+CYP2D6","Brexpiprazole","CYP2D6","pre/post","Psychiatry","Prolactenemia, increased levels of blood creatine kinase, schizophrenia, seizures, insomnia, GI symptoms, foot fracture, musculoskeletal pain ","CYP2D6*10 :  CYP2D6*41:  CYP2D6*4 :  CYP2D6*5 :  CYP2D6*14A :  CYP2D6*14 : CYP2D6*18 :  CYP2D6*21"],
    ["Dean, L.",2018,"Brivaracetam Therapy and CYP2C19 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK500036/","Brivaracetam","CYP2C19","pre/post","Neurology","sedation, fatigue, dizziness, and nausea","CYP2C19*2 : CYP2C19*3"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Busulfan","CYP2C9 : GSTA1","pre/post","Oncology ","Myelosuppression, nausea and vomiting, interstitial pulmonary fibrosis, gynecomastia, Addisonian symptoms, dermatologic hyperpigmentation, and cytologic dysplasia.","CYP2C9*2 (c.430C>T) rs1799853 : GSTA1*B (c.-135T>C)  rs3957357"],
    ["Zanini Maciel, L.M., et al.",2017,"Medullary thyroid carciNoma – Adverse events during systemic treatment: risk-benefit ratio","http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017005004103&lng=en&nrm=iso&tlng=en","Cabozantinib","RET","post","Oncology","Perforation, fistulas, and hemorrhages. May have interaction with CYP3A4 inhibitors as well. ","RET"],
    ["Grimaldi, E., et al.",2017,"New advances in DPYD genotype and risk of severe toxicity under capecitabine","https://www.ncbi.nlm.nih.gov/pubmed/28481884","Capecitabine","DPYD","pre/post","Oncology","Risk of life-threatening capecitabine toxicity, such as bone marrow suppression and neurotoxicity.","DPYD*2A:  DPYD*13, and rs67376798"],
    ["Gross, E., et al. ",2008,"Strong association of common dihydropyrimidine dehydrogenase gene polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004003","Capecitabine","DPYD","pre/post","Oncology","Neutropenia, thrombopenia, mucositis, diarrhea, nausea and vomiting, neurotoxicity, cardiac toxicity, alopecia and hand-foot-syndrome ","thrombopenia,"],
    ["Caudle, K.E., et al.",2014,"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206662/","Carbamazepine","HLA-B","pre/post","Neurology","Induced Steven Johnson Syndrome and Toxic Epidermal Necrolysis","HLA-B*15:02"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Carbamazepine","HLA-B","peri","Neurology","SJS/TEN","HLA-B*15:02 (and other alleles of B75 serotype)"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Carbamazepine","HLA-A","peri","Neurology","DRESS, MPE, SJS/TEN","HLA-A*31:01"],
    ["Krasowski, M. ",2015,"Current Diagnosis & Treatment : Family Medicine Chapter 49: Pharmacogenomics","http://accessmedicine.mhmedical.com/content.aspx?bookid=1415&sectionid=77060358","Carbamazepine","HLA-B","pre","Neurology","Steven-Johnson syndrome and toxic epidermal necrolysis","HLA-B*1502"],
    ["Ueda, K., et al.",2007,"Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity.","https://www.ncbi.nlm.nih.gov/pubmed/17465707?access_num=17465707&link_type=MED&dopt=Abstract","Carbamazepine","GSTM1","pre","Neurology","mild hepatotoxicity ","GSTM1-"],
    ["Pirmohamed, M. ",2010,"Pharmacogenetics of adverse drug reactions ","https://www.researchgate.net/profile/Munir_Pirmohamed/publication/40697565_Pharmacogenetics_of_Idiosyncratic_Adverse_Drug_Reactions/links/09e4150fd81a89a128000000.pdf","Carbamazepine","HLA-E, HLA-A*3101:MLN:TNG-308:HLA-DR3:HLA-DQ2:HSPA1L:HLA-B*1502","pre/post","Neurology ","HLA-E and HLA-A*3101 were implicated in carbamazepine induced maculopapular rash in Han Chinese populations. MLN was implicated in carbamazapine hypersensitivity in Han Chinese populations. TNF-308, HLA-DR3, HLA-DQ2 and HSPA1L were implicated in carbamazapine hypersensitivity in Caucasian populations. HLA-B*1502 was implicated in carbamazpine induced SJS/TEN in Han Chinese populations.","HLA-E, HLA-A*3101"],
    ["Lazier, J., et al.",2014,"Hyperammonemic encephalopathy in an adenocarcinoma patient managed with carglumic acid.","https://www.ncbi.nlm.nih.gov/pubmed/25302046","Carglumic Acid","NAGS","pre","Genetic","Hyperammonemic encephalopathy","No specific polymorphism applicable: referencing NAG deficiency"],
    ["Dean, L., et al.",2017,"Carisoprodol Therapy and CYP2C19 Genotype.","https://www.ncbi.nlm.nih.gov/pubmed/28520382","Carisoprodol","CYP2C19","pre/post","Cardiology","Increased risk of death, CNS respiratory depression, and seizures","CYP2C19*2 : CYP2C19*3 :  CYP2C19*4 : CYP2C19*5 :  CYP2C19*6 :  CYP2C19*7 : CYP2C19*8"],
    ["Luzum J.A., et al.",2017,"CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.","https://www.ncbi.nlm.nih.gov/pubmed/28181117","Carvedilol","CYP2D6","pre/post","Cardiology","Dizziness ","CYP2D6*4"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Celecoxib","CYP2C9","pre/post","Cardiology, Anesthesiology","Cardiovascular and gastrointestinal bleeding events.","CYP2C9*3/*3"],
    ["Dean, L.",2016,"Celecoxib Therapy and CYP2C9 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK379478/","Celecoxib","CYP2C9","pre/post","Rheumatology","Poor metabolizers (individuals who carry two copies of the variants CYP2C9*2 or CYP2C9*3 or a loss-of-function of the CYP2C9) are at increased risk of high celecoxib levels. Increased risk of bleeding in CYP2C9*3 and NSAID use.","CYP2C9*2:CYP2C9*3"],
    ["Ishikawa, C., et al.",2004,"A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin","https://www.ncbi.nlm.nih.gov/pubmed/15365880","Cerivastatin","CYP2C8: OATP2: OATP1B1 : (SLCO1B1)","pre/post","Cardiology","Rhabdomyolysis","475delA, G874C, and T1551C, were found in the exons of CYP2C8."],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Cetuximab","VNTR3","pre/post","Oncology ","Pulmonary toxicity, Interstitial lung disease, Skin toxicity, and Acneiform rash","VNTR3/VNTR3"],
    ["Greenfield, N.P., et al.",2012,"PharmacogeNomic biomarkers in dermatologic drugs","https://www.tandfonline.com/doi/full/10.3109/09546634.2012.697989?scroll=top&needAccess=true","Cevimeline","CYP2D6 and CYP3A4","post","Rheumatology","Nausea, increased sweating, rhinitis, diarrhea  ","Drugs that inhibit CYP2D6 and CYP3A4 inhibit the metabolism of ceimeline"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Chloroquine","G6PD","pre/post","Infectious Disease","Cause hemolytic anemia in patients with G6PD deficiency.","G6PD C563T "],
    ["Janney, S.K., et al.",1986,"Excess release of ferriheme in G6PD-deficient erythrocytes: possible cause of hemolysis and resistance to malaria","http://www.bloodjournal.org/content/67/2/331.short?sso-checked=true","Chloroquine","G6PD","pre/post ","Infectious Disease","hemolysis in G6PD deficiency",""],
    ["Pavlic, G.J.",1966,"Possible Potentiation of Hemolytic Anemia by Tolbutamide","https://jamanetwork.com/journals/jama/article-abstract/660309","Chlorpropamide","G6PD","pre/post ","Endocrinology","Hypoglycemia, dizzines, headache, liver failure, aplastic anemia",""],
    ["Ross, C.J.D, et al.",2009,"Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy","https://www.nature.com/articles/ng.478?foxtrotcallback=true","Cisplatin","TPMT","post","Oncology","Cisplatin induced ototoxicity","rs12201199"],
    ["Hicks, J.K., et al.",2015,"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","http://onlinelibrary.wiley.com/doi/10.1111/jcpt.12320/full","Citalopram","CYP2D6","peri","Psychiatry","Defective CYP2D6 alleles slow metabolizer of citalopram","CYP2D6*3:CYP2D6*4:CYP2D6*5:CYP2D6*6"],
    ["Rudberg, I., et al.",2007,"Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients","http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100291/full","Citalopram","CYP2C19","peri","Psychiatry","Defective CYP2C19 alleles produce lower serum concentration of escitalopram and increased risk of therapeutic failure","CYP2C19*17"],
    ["Contin, M., et al.",2002,"Evidence of Polymorphic CYP2C19 Involvement in the Human Metabolism of N-Desmethylclobazam","https://www.ncbi.nlm.nih.gov/pubmed/12451290","Clobazam","CYP2C19","peri","Neurology","sedation, dizziness, and fatigue","CYP2C19*2:CYP2C19*3:CYP2C19*4"],
    ["Brandl, E.J., et al.",2013,"Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder","https://www.nature.com/articles/tpj201312","Clomipramine","CYP2D6","pre/post","Psychiatry","Drug resistance and higher dose requiremetn. Duration of illness did not differ between patients with different CYP2D6","rs35742686:rs3892097:rs1065852:rs28371706:rs28371725"],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Clopidogrel ","CYP2C19","pre/post","Cardiology/Hematology","Adverse cardiovascular events, stent thrombosis - CYP2C19 Poor Metabolizers decrease the antiplatelet effect. Increased likelihood of requiring antiplatelet therapy as a combined therapy. ","CYP2C19*2:CYP2C19*3:CYP2C19*4:CYP2C19*5:CYP2C19*6:CYP2C19*7:CYP2C19*8 (Poor Metabolizers); CYP2C19*17:CYP2C19*(Increase enzyme activity)"],
    ["Dean, L.",2017,"Prasugrel therapy and CYP Genotype","https://www.ncbi.nlm.nih.gov/books/NBK425796/","Clopidogrel","CYP2C19","pre/post","Cardiology/Hematology","Increased risk for High on Treatment Platelet Reactivity in patients with No function in CYP2C19 due to decreased active metabolites of clopidogrel. The polymorphism responsible is CYP2C19*2 which leads to reduced plasma active clopidogrel metabolites and therefore increased platelet reactivity.","CYP2C19*2"],
    ["Kelly, R.P., et al.",2012,"Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248259/","Clopidogrel","CYP2C19","pre/post","Cardiology/Hematology","Increased risk of bleeding, stent thrombosis, and major adverse cardiovascular events. Bleeding related effects such as post-procedural bleeding and contusion. Patients with lower body weight presented a higher incidence of contusion related to the drug.- Poor responders and Non responders of clopidogrel due to reduced metabolism by polymorphic CYP2C19 enzymes, thus reduced therapeutic effect in cardiovascular patients. ","CYP2C19*2:CYP2C19*3:CYP2C19*17:rapid metabolizer (phenotype*1/*1):intermediate metabolizer (phenotype *1/*2 & *1/*3); poor metabolizer (phenotype *2/*2 and *2/*3)"],
    ["Simon, T., et. al.",2009,"Genetic Determinants of Response to Clopidogrel and Cardiovascular Events","https://www.ncbi.nlm.nih.gov/pubmed/19106083","Clopidogrel","ABCD1","pre/post","Cardiology/Hematology","Increased risk of death, Nonfatal myocardial infarction, or stroke","ABCB1 (TT at nucleotide 3435)"],
    ["Preissner, S.C.",2013,"Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858335/?report=reader","Clopidrogel","CYP2C19 : CYP2B6","pre/post","Cardiology/Hematology","CYP 2C19*2 polymorphism was shown to lead to a 30% increased risk of major adverse cardiovascular events during treatment with clopidogrel; CYP 2B6*5 and P2Y12 polymorphisms are also associated with clopidogrel resistance","CYP2C19*2:CYP2B6*5"],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Clotrimoxazole","G6PD deficiency","pre/post","Infectious Disease","acute hemolytic anemia due to G6PD deficiency","G6PD  "],
    ["Dean, L.",2016,"Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes","https://www.ncbi.nlm.nih.gov/books/NBK367795/","Clozapine","CYP2D6","pre","Psychiatry","Higher than expected plasma concentrations of clozapine with usual doses","CYP2D6*9:CYP2D6*10:CYP2D6*17:CYP2D6*29:CYP2D6*36:CYP2D6*41"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Clozapine","HLA-DRB","pre","Psychiatry ","Agranulocytosis","HLA-DRB5*0201"],
    ["Ribas, A., et al.",2014,"Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study","https://www.sciencedirect.com/science/article/pii/S1470204514703018","Cobimetinib","BRAF","pre","Oncology","Fatigue:diarrhea:Non-acneiform rash:liver enzyme abnormalities:photosensitivity","BRAFV600"],
    ["Dean, L.",2012,"Codeine Therapy and CYP2D6 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK100662/","Codeine","CYP2D6","pre/post","Anesthesiology","Risk for morphine toxicity (eg. Extreme sleepiness, confusion, shallow breathing, fatal respiratory depression, and death) in the ultrarapid metabolizer patients. Insufficient pain relief in poor metabolizers, avoid use of codeine due to lack of efficacy).","CYP2D6*1/*1xN,*1/*2xN (ultrarapid metabolizer): CYP2D6*1/*1,*1/*2,*2/*2,*1/*41,*1/*4,*2/*5,*1/*10(Normal metabolizer):CYP2D6*4/*10,*5/*41(intermediate metabolizer): CYP2D6*4/*4,*4/*5,*5/*5,*4/*6(poor metabolizer)"],
    ["Camidge, D.R., et al.",2012,"Activity and safety of crizotinib in patients with ALK-positive Non-small-cell lung cancer: updated results from a phase 1 study","https://www.sciencedirect.com/science/article/pii/S1470204512703443","Crizotinib","ALK","post","Oncology","Diarrhea, constipation, nausea, vomiting and visual side-effects","EML4–ALK"],
    ["Awad, M.M., et al.",2013,"Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1","https://www.nejm.org/doi/full/10.1056/NEJMoa1215530","Crizotinib","ROS1","post","Oncology","Acquired mutation affecting the ROS1 kinase domain that confers resistance to crizotinib","CD74–ROS1"],
    ["Nagasundaram, N., et al.",2017,"Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors.","https://www.ncbi.nlm.nih.gov/pubmed/28332225","Crizotinib","ALK","pre/post","Oncology"," Medication resistance against Non squamous cell lung cancer and cancer recurrence ","ALK L1196M : ALK G1269A"],
    ["Zanger, U., et al.",2013,"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588594/","Cyclophosphamide","CYP2B6","pre/post","Oncology","Myelosuppression, hemorrhagic cystitis, alopecia, and gonadal damage","CYP2B6*6 :CYP2B6*18"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Cyclophosphamide","CYP2C19","pre/post","Oncology ","Myelosuppression, hemorrhagic cystitis, alopecia, and gonadal damage are the main toxic effects. ","CYP2C19*2 : CYP2C19*3 "],
    ["Xie, H., et al.",2006,"Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.","https://www.ncbi.nlm.nih.gov/pubmed/16183265?dopt=Abstract","Cyclophosphamide","CYP2B6","pre/post","Oncology ","Myelosuppression, hemorrhagic cystitis, alopecia, and gonadal damage","CYP2B6 G516T"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Cyclosporine","ABCB1","pre/post","Oncology","Nephrotoxicity","ABCB1 34355TT"],
    ["Hauschild, A., et al.",2012,"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","https://www.sciencedirect.com/science/article/pii/S014067361260868X","Dabrafenib","BRAF","post","Oncology","Skin-related toxic effects, fever, fatigue, arthralgia, and headache","BRAFV600E "],
    ["Dean, L.",2017,"Dabrafenib Therapy and BRAF and G6PD genotype","https://www.ncbi.nlm.nih.gov/books/NBK447415/","Dabrafenib","G6PD","post","Oncology","Potential risk of hemolytic anemia in patients with G6PD deficiency.","p.Ser218Phe:p.Asn126Asp:p.Ser218Phe"],
    ["Jang, S, et al.",2013,"Which drug, and when, for patients with BRAF-mutant melanoma?","http://www.sciencedirect.com/science/article/pii/S1470204512705399","dabrafenib","BRAF, mainly at codon 600, which result in constitutive activation of the MAPK pathway","pre/post","Oncology","growth of cutaneous squamous-cell carcinomas","BRAF, mainly at codon 600, which result in constitutive activation of the MAPK pathway"],
    ["Samatar, A.A., et al.",2014,"Targeting RAS-ERK signalling in cancer: promises and challenges","https://www.nature.com/articles/nrd4281","Dabrafenib","RAS","post","Oncology","Benign tumours of the skin, mainly keratoacanthomas and squamous cell carciNomas","V600E"],
    ["Morio, R., et al.",2017,"Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C","https://link.springer.com/article/10.1007/s00535-016-1255-4","Daclatasvir","IFNL4","post","Infectious Disease","flulike syndrome, aminotransferase level elevation, HCV clearance","ss469415590, IFNL4 TT/?G genotype or IFNL4 ?G/?G genotype in in older patients"],
    ["Abouraya, M., et al.",2013,"Dapsone?Associated Methemoglobinemia in a Patient With Slow NAT2*5B Haplotype and Impaired Cytochrome b5 Reductase Activity","https://accp1.onlinelibrary.wiley.com/doi/pdf/10.1177/0091270010393343","Dapsone","CYB5R3: NAT2*5B: CYB5A","pre","Dermatology","Methemoglobinemia on low prophylactic dosage of dapson","NAT2*5B haplotype, along with low CYB5A and CYB5R3 expression and b5/ b5R reduction activity."],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Dapsone","G6PD","pre","Dermatology","Acute Hemolytic anemia","G6PD A-"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Dapsone","G6PD","pre/post","Infectious Disease","Cause hemolytic anemia in patients with G6PD deficiency.","G6PD C563T "],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Dapsone","G6PD deficiency","pre/post","Infectious Disease","acute hemolytic anemia due to G6PD deficiency","G6PD  "],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Dapsone","HLA-B","peri","Infectious Disease","Dapsone hypersensitivity syndrome","HLA-B*13:01"],
    ["Kerbusch, T., et al.",2003,"Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability","http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2125.2003.01967.x/full","Darifenacin","CYP2D6","pre","Urology","Up to 90% increase in absolute bioavailability of darifenacin in poor CYP2D6 metabolizers; lower CYP2D acitivity in females","Carries of poor metabolizer genotype"],
    ["Feld, J.J., et al.",2015,"Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks","https://www.sciencedirect.com/science/article/pii/S0168827815006765","Dasabuvir, Ombitasvir, Paritaprevir, and Ritonavir","IL28B","peri","Infectious Disease","fatigue, diarrhea, and headache","Non-CC genotype"],
    ["Soverini, S., et al.",2014,"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","https://www.sciencedirect.com/science/article/pii/S0145212613003287","Dasatinib","BCR-ABL1 ","peri","Oncology","Clinical resistance to dasatinib","V299L, T315A, F317L/I/V/C"],
    ["Zabriskie, M.S., et al.",2014,"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160372/","Dasatinib","BCR-ABL1","pre/post","Oncology","Relapse of disease- Mutations in BCR-ABL1 may confer resistance and treatment failure leading to disease progression. T315I mutants are also found to confer high-level resistance to Tyrosine Kinase Inhibitors.","BCR-ABL1:M244, G250, Q252, Y253, E255, V299, F311, T315, F317, M351, F359, and H396:T315I"],
    ["Anandakumar, P., et al.",2014,"Drug induced hepatotoxicity - A Review","http://ajplronline.org/UploadFile/635572387967182322.pdf","Debrisoquine","P-450-II-D6","pre/post","Cardiology","Poor metabolism of drug","-"],
    ["Jurkat-Rott, K., et al.",1999,"Genetics and pathogenesis of malignant hyperthermia","http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-4598(200001)23:1%3C4::AID-MUS3%3E3.0.CO;2-D/full","Desflurane","RYR1","intra","Anesthesiology","Suceptibility to malignant hyperthermia",""],
    ["MoriNobu, S., et al.",1997,"Effects of genetic defects in the CYP2C19 gene on the N-demethylation of irnipramine, and clinical outcome of imipramine therapy","https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1440-1819.1997.tb02593.x","Desipramine","CYP2C19","pre/post","Psychiatry","Impaired N-demethylation of imipraniine","CYP2C19M1, CYP2C19 M2"],
    ["Liu, J.F., et al.",2017,"Chapter Fourteen - A Decade of Deuteration in Medicinal Chemistry","https://www.sciencedirect.com/science/article/pii/S0065774317300180","Deutetrabenazine","CYP2D6","pre/post ","Neurology ","increase half life of active metabolites","Poor metabolizers of CYP2D6 or strong inhibitors of CYP2D6"],
    ["Goldstein, J.A.",2001,"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","http://onlinelibrary.wiley.com/doi/10.1046/j.0306-5251.2001.01499.x/full","Diazepam","CYP2C19","pre/post","Neurology/Anesthesiology","Poor metabolisers of drug can experience toxicity.","Poor metabolizer genotype"],
    ["Dean, L.",2016,"Diazepam Therapy and CYP2C19 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK379740/","Diazepam","CYP2C19","pre","Psychiatry"," Sedation, anxiolysis, anticonvulsant muscle relaxant, amnesic effects, as well as higher benzodiazepine withdrawal symptoms which may include seizures.","CYP2C19*1 : CYP2C19*2 : CYP2C19*3 : CYP2C19*17"],
    ["Zanger, U., et al.",2013,"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.","https://www.sciencedirect.com/science/article/pii/S0163725813000065","Diclofenac","CYP2C9","peri","Pain Management/Rheumotology/Neurology/Dermotology","? drug clearance & ? adverse events (NSAIDS)","CYP2C9*3"],
    ["Daly, A., et al. ",2007,"Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes","http://www.sciencedirect.com/science/article/pii/S0016508506024784","Diclofenac","UGT2B7 : ABCC2 ","pre/post","Rheumatology","Drug-induced liver injury that ranges from acute liver failure to nonspecific symptoms with transaminase elevation","UGT2B7*2 :  ABCC2 C-24T"],
    ["Hoffmeyer, S., et al.",2002,"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein","http://onlinelibrary.wiley.com/doi/10.1067/mcp.2002.126177/full","Digoxin","MDR1","peri","Cardiology","Increased digoxin plasma levels, altered absorption and/or disposition profiles of digoxin and P-glycoprotein-mediated drug interaction.","C3435T"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Docetaxel","ABCB1 ","pre/post","Oncology","Neutropenia","ABCB1 c.1236T>C rs1128203 : ABCB1 c.3435T>C rs1045642"],
    ["Chen, S., et al.",2013,"Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics","https://www.futuremedicine.com/doi/full/10.2217/pgs.13.190","Dolutegravir","UGT1A1","pre/post","Infectious Disease","decreased oral clearance","*1/*6:*1/*28:*1/*37:*28/*36:*36/*37"],
    ["Haritos, V. S., et al.",2000,"Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin","https://www.ncbi.nlm.nih.gov/pubmed/11037801","Doxepin","CYP2D6","pre/post","Psychiatry","Doxepin increased hydroxylation with mutation",""],
    ["Koski, A., et al.",2007,"A Fatal Doxepin Poisoning Associated With a Defective CYP2D6 Genotype","https://www.ncbi.nlm.nih.gov/pubmed/17721180","Doxepin","CYP2C19","pre/post","Psychiatry","Poor metabolizer","*3/*4"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Doxorubicin","ABCB1 : SLC22A16","pre/post","Oncology","Cardiotoxicity","ABCB1 c.1236T>C rs1128203:  ABCB1 c.2677T>A/G rs2032582 : SLC22A16 c.146A>G  rs714368 : SLC22A16 c.312T>C rs6907567"],
    ["Dorado, P., et al. ",2007,"CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.","http://www.ingentaconnect.com/content/ben/cdt/2006/00000007/00000012/art00013","Duloxetine","CYP2D6","pre/post","Psychiatry","Personality characteristics of social cognitive anxiety and midl psychotic like symptoms - due to null CYP2D6 activity. This can be a risk of vulnerability to disease in schizophrenia patients.","CYP2D6*3"],
    ["Sánchez, M.A., et al.",2013,"Impact of pharmacogenetics on CNS side effects related to efavirenz.","https://www.ncbi.nlm.nih.gov/pubmed/23859571","Efavirenz","CYP2B6","pre/post","Infectious Disease","CNS toxicity- due to concentrations of efavirenz above the therapeutic range, mostly due to CYP2B6*6 (516G>T and 785A>G) polymorphysm. ","CYP2B6*6 (516G>T and 785A>G) "],
    ["Chonlaphat, S.",2012,"Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522814/","Efavirenz","CYP2B6","post","Infectious Disease","GAC-CYP2B6 haplotype is associated with higher plasma efavirenz concentrations in HIV-infected Thai adults.","GAC-CYP2B6"],
    ["Dhoro, M., et al.",2015,"CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.","https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-015-0004-2","Efavirenz","CYP2B6","pre/post","Infectious Disease","decreased efavirenz clearance in CYP2B6*6TT genotype, therefore it is recommended a dose reduction to 200 mg/day in this genotype. CYP2B6*18 and CYP2B6*6 both show increased efavirenz levels and study results demonstrate that these polymorphisms can have additive effects if both are present. ","CYP2B6*6TT (516G?>?T and 785A?>?G) : CYP2B6*18"],
    ["Becquemont, L.",2017,"Type 1 Gaucher disease (CYP2D6-eliglustat)","https://www.sciencedirect.com/science/article/pii/S0040595717300124","Eliglustat","CYP2D6","pre/post","Genetic","Contraindicated for ultra-rapid metabolizers (underdosing inefficacy) or slow metabolizer due to drug toxicity","CYP2D6 ultra-rapid metabolizers: CYP2D6 slow metabolizers"],
    ["Rosenberg, H., et al. ",2003,"Malignant Hyperthermia Susceptibility","https://www.ncbi.nlm.nih.gov/books/NBK1146/","Enflurane","RYR1: CACNA1S","intra","Anesthesiology","Malignant hyperthermia","RYR1: CACNA1S (p.Arg174Trp)"],
    ["Wang, C., et al.",2018,"Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904969/","Erlotinib","UGT3A1","pre/post","Oncology","Skin rash and/or digestive tract injury","rs10045685"],
    ["Al-Abdi, S.Y.",2017,"Prolonged indirect hyperbilirubinemia in a moderately preterm boy with Mediterranean glucose-6-phosphate dehydrogenase and glutathione S-transferase Mu 1 null mutations.","http://casereports.bmj.com/content/2017/bcr-2016-218404.abstract","Erythromycin","G6PD","pre/post","Infectious Disease","Indirect hyberbilirubinemia","G6PD"],
    ["Hicks, J.K., et al.",2015,"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors.","http://onlinelibrary.wiley.com/doi/10.1002/cpt.147/full","Escitalopram","CYP2C19","pre/post","Psychiatry","Affects drug efficacy and safety","CYP2C19 carriers with poor metabolizer genotypes"],
    ["Noehr?Jensen, L., et al.",2009,"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors.","http://onlinelibrary.wiley.com/doi/10.1002/cpt.147/full","Escitalopram","CYP2D6","pre/post","Psychiatry","Affects drug efficacy and safety",""],
    ["Dean, L. ",2012,"Esomeprazole Therapy and CYP2C19 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK100896/","Esomeprazole","CYP2C19","pre","Gastroenterology","increased risk of C.difficile infections and osteoporosis-related fractures.","CYP2C19*17 : CYP2C19*1/*1 : CYP2C19*1/*2 : CYP2C19*1/*3 :  CYP2C19*2/*17 : CYP2C19*3/*17 :  CYP2C19*2/*2 :  CYP2C19*2/*3 : CYP2C19*3/*3"],
    ["Kagami, T., et al.",2016,"Potent acid inhibition by voNoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.","http://onlinelibrary.wiley.com/doi/10.1111/apt.13588/full","Esomeprazole","CYP2C19","pre/post","Gastroenterology","Differences in metabolism of drug.","CYP2C19*2"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Esomeprazole","CYP2C19","pre/post","Gastroenterology","ventilator acquired pneumonia (poor metabolizers). FM who are taking PPIs as part of H.pylori drug regime experience little or No benefit from PPIs.PM have increased drug efficacy and better clinical outcomes. However, prolonged hypochloridia associated w/increased risk of C. difficile infections and osteoporosis-related fractures.","CYP2C19*2"],
    ["Felix, C.A., et al.",1998,"Association of CYP3A4 genotype with treatment related leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC23750/","Etoposide","CYP3A4","post ","Oncology","Increased metabolism of epipodophylotoxin to catechol and quiNone metabolites have potential genotoxic properties and MLL translocations","CY3A4-W"],
    ["Rocha, J.C.C, et al.",2017,"Pharmacogenetics of outcome in children with acute lymphoblastic leukemia","http://www.bloodjournal.org/content/105/12/4752.long?sso-checked=true","Etoposide","GSTM1 ","post","Oncology","Drug resistance, hematological relapse ","GTSM 1 deletion and interaction with TYMS and NR3C1 genotypes"],
    ["Malhotra, B., et al.",2008,"Pharmacokinetic profile of fesoterodine.","http://europepmc.org/abstract/med/19000553","Fesoterodine","CYP2D6","pre/post","Urology","CYP2D6 status had no effect on time to reach Cmax (5 h), renal clearance (approximately 250 ml/min), or half-life (approximately 8 h).","-"],
    ["FDA Drug Label ",2017,"Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6 | PharmGKB","https://www.pharmgkb.org/label/PA166153432","Flibanserin","CYP2C9","pre/post","Gynecology","Change in drug efficacy ","CYP2C9"],
    ["FDA Drug Label ",2017,"Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6 | PharmGKB","https://www.pharmgkb.org/label/PA166153432","Flibanserin","CYP2C19","pre/post","Gynecology","syncope","poor or extensive CYP2C19 metabolizers"],
    ["FDA Drug Label ",2017,"Annotation of FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6 | PharmGKB","https://www.pharmgkb.org/label/PA166153432","Flibanserin","CYP2D6","pre/post","Gynecology","Lower clearance","poor metabolizers of CYP2D6"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Flucloxacillin","HLA-B","pre/post","Infectious Disease","drug-induced liver injury","HLA-B*5701"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Flucloxacillin","HLA-B","pre/post ","Infectious Disease","DILI drug-induced liver injury","HLA-B*57:01"],
    ["Meulendijks, D., et al. ",2016,"Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines","https://www.ncbi.nlm.nih.gov/pubmed/27544765","Fluoropyrimidines","DPYD","pre/post","Oncology","Increase the risk of fluoropyrimidine-associated toxicity,","DPYD variant c.1129-5923C>G/HapB3"],
    ["Boige, V., et al.",2016,"DPYD Genotyping to predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.","https://jamanetwork.com/journals/jamaoncology/fullarticle/2482915","Fluorouracil","DPYD","pre/post","Dermatology","Hematologic","DPYD*6"],
    ["Seck, K., et al.",2005,"Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals.","http://clincancerres.aacrjournals.org/content/11/16/5886.short","Fluorouracil","DPYD","pre/post","Oncology","Decreased enzyme activity in dihydropyrimidine dehydrogenase.","1601G>A (Ser534Asn) and 2846A>T (Asp949Val)"],
    ["Haufroid, V., et al.",2015,"CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.","http://www.tandfonline.com/doi/abs/10.3109/15563650.2015.1049355","Fluoxetine","CYP2D6","pre/post","Psychiatry","CYP2D6 poor metabolizers are generally more prone to adverse effects.","CYP2D6 carriers with poor metabolizer genotypes"],
    ["Vogl, S., et al.",2015,"CYP2C9 Genotype vs. Metabolic Phenotype for Individual Drug Dosing—A Correlation Analysis Using Flurbiprofen as Probe Drug.","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120403","Flurbiprofen","CYP2C9","peri","Rheumatology","Bleeding complications","CYP2C9 alleles *2 and *3"],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Fluvastatin","ABCG2","pre/post","Cardiology","Myopathy","ABCG2 c.421A"],
    ["Mirosevic Skvrce, N., et al.",2013,"CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renaltransplant patients taking fluvastatin: a case-control study.","https://www.ncbi.nlm.nih.gov/pubmed/?term=CYP2C9+and+ABCG2+polymorphisms+as+risk+factors+for+developing+adverse+drug+reactions+in+renal+transplant+patients+taking+fluvastatin%3A+a+case–control+study","Fluvastatin","CYP2C9","pre/post","Cardiology","Myotoxicity, cognitive loss, neuropathy, pancreatic, hepatic and sexual dysfunctions ","CYP2C9*2 : CYP2C9*3"],
    ["Boér, K.",2017,"Fulvestrant in advanced breast cancer: evidence to date and place in therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502950/","Fulvestrant","TFAP2C","pre/post","Oncology","Decreased response to fulvestrant","-"],
    ["Campbell, N.L., et al.",2016,"Tolerability of acetylcholinesterase inhibitors by CYP2D6 activity.","http://aanddjournal.net/article/S1552-5260(16)31115-3/fulltext","Galantamine","CYP2D6","pre/post","Neurology","Slow metabolisers may experience nausea, dissiness, insomnia","Carriers with CYP2D6 slow metabolizer genotype"],
    ["Ruan, Y, et al.",2016,"Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.","https://www.nature.com/articles/srep23368","Gefitinib","CYP3A4, CYP3A5 and CYP2D6","pre/post","Oncology"," Gefitinib-induced skin rash and diarrhea ","EGFRm+ (L858R, exon 19 deletions [19 different mutations] and T790M)"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Gefitinib","ABCG2","pre/post","Oncology","Gefitinib-induced diarrhea","Q141K variant of ABCG2"],
    ["Zanger, U., et al.",2013,"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.","https://www.sciencedirect.com/science/article/pii/S0163725813000065","Glimepiride","G6PD","pre/post","Endocrinology","? drug clearance & ? adverse events (sulfonylurea hypoglycemic drugs)","CYP2C9*3"],
    ["Zanger, U., et al.",2013,"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.","https://www.sciencedirect.com/science/article/pii/S0163725813000065","Glipizide","G6PD","pre/post","Endocrinology","? drug clearance & ? adverse events (sulfonylurea hypoglycemic drugs)","CYP2C9*3"],
    ["Zanger, U., et al.",2013,"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.","https://www.sciencedirect.com/science/article/pii/S0163725813000065","Glyburide","G6PD","pre/post","Endocrinology","? drug clearance & ? adverse events (sulfonylurea hypoglycemic drugs)","CYP2C9*3"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Haloperidol","CYP2D6","pre/post","Psychiatry","Poor metabolizers have higher risk of pseudoparkinsonism and experience adverse effects on standard doses. ","CYP2D6*3: CYP2D6*4: CYP2D6*5: CYP2D6*6"],
    ["Diaz-Sylvester, P.L., et al.",2009,"Halothane modulation of skeletal muscle ryanodine receptors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2465464/","Halothane ","RyR1","intra","Anesthesiology","Malignant hyperthermia (MH","Gly4932Ser "],
    ["Spinasse, L.B., et al.",2014,"Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.","https://www.futuremedicine.com/doi/abs/10.2217/pgs.13.202?journalCode=pgs&","Hydralazine","Nonspecific (NAT)","peri","Cardiology","Tachycardia, fluid retention, headache","NAT2"],
    ["Lipsky, A.H., et al.",2015,"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.","http://www.haematologica.org/content/haematol/early/2015/09/28/haematol.2015.126672.full.pdf","Ibrutinib","Chromosome 11q","pre/post","Oncology","Bleeding or bruising","11q deletion"],
    ["O'Brien, S., et al.",2016,"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.","https://www.sciencedirect.com/science/article/pii/S1470204516302121","Ibrutinib","Chromosome 17p","pre/post","Oncology","Death, Major bleeding, infections (pneumonia)","17p deletion"],
    ["Miyako, M., et al.",2017,"Hepatic IFNL4 expression is associated with Non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.","https://www.ncbi.nlm.nih.gov/pubmed/28036111","IFN alpha-based therapy","IFNL4","peri","Infectious Disease","poor response to IFN alpha-based therapy in HCV infection","IFNL4-?G genotype"],
    ["Brennan, M.D.",2014,"Pharmacogenetics of second-generation antipsychotics.Pharmacogenomics 15.6 (2014): 869-884","https://www.ncbi.nlm.nih.gov/pubmed/?term=genetic+variants+drug+Iloperidone","Iloperidone","CYP2D6","pre","Psychiatry","Weight gain and metabolic side effects, including diabetes and dyslipidemia. cardiac complications, most Notably dysrhythmias including prolongation of the QT interval. elevate serum prolactin levels, resulting in hypogonadism and dysregulation of hypothalamic–pituitary axis function.","CYP2D6*3: CYP2D6*4: CYP2D6*5"],
    ["Eum, S., et al.",2016,"Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067149/","Iloperidone","CYP2D6","pre/post","Psychiatry","CNS depression, hypotension when used with other alpha-1 antagonist, ","CYP2D6*9 :  CYP2D6*10 : CYP2D6*17 :  CYP2D6 *29 :  CYP2D6 *36 : CYP2D6*41"],
    ["David, M., et al.",2007,"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.","https://www.ncbi.nlm.nih.gov/pubmed/16960151?dopt=Abstract","Imatinib","PDGFRB","pre/post ","Oncology","This is a positive effect on the treatment of Myelodysplastic Syndrome / Myeloproliferative Disease (MDS/MPD) with translocations of 5q31–35. Imatinib might be effective in the treatment of patients with this specific PDGFRB rearrangement.","ETV6-PDGFRB fusion gene"],
    ["Lyu, X., et al. ",2016,"A Novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia","https://molecularcytogenetics.biomedcentral.com/articles/10.1186/s13039-016-0257-5","Imatinib","BCR-ABL","pre/post ","Oncology","Resistance to treatment with Imatinib ","BCR-ABL1mutations: M244: G250: Q252: Y253: E255: V299: F311: T315: F317: M351: F359: H396: T315I "],
    ["Pardanani, A., et al.",2006,"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","http://www.sciencedirect.com/science/article/pii/S014521260500442X","Imatinib","FIP1L1-PDGFRA","pre/post ","Oncology","Imatinib treatment resistance in pts with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia the FIP1 like 1–platelet-derived growth factor receptor alpha T674I mutation.","FIP1L1-PDGFR? (T674I) mutant."],
    ["Speight, R.A., et al.",2013,"Rare, Germline Mutation of KIT With Imatinib-Resistant Multiple GI Stromal Tumors and Mastocytosis","http://ascopubs.org/doi/full/10.1200/JCO.2012.42.0133","Imatinib","KIT","pre/post ","Oncology","D816V mutation of c-Kit are Not sensitive to Gleevec (imatinib mesylate).","D816V c-Kit mutation"],
    ["Zabriskie, M.S., et al.",2014,"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160372/","Imatinib","BCR-ABL1","pre/post","Oncology","Relapse of disease- Mutations in BCR-ABL1 may confer resistance and treatment failure leading to disease progression. T315I mutants are also found to confer high-level resistance to Tyrosine Kinase Inhibitors.","BCR-ABL1:M244, G250, Q252, Y253, E255, V299, F311, T315, F317, M351, F359, and H396:T315I"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Imatinib","ABCB1 : ABCG2 : SLC22A1","pre/post","Oncology ","Influence the pharmacokinetics of drug, Pulmomary fibrosis.","ABCB1 c.1236T>C  rs1128203 : ABCB1 c.2677T>A/G rs2032582 :  ABCB1 c.3435T>C  rs1045642 :  ABCB1 Hap*4 : ABCG2 c.421C>A  rs2231142 : SLC22A1 c.480C>G  rs683369"],
    ["Zhou, Z.W., et al.",2015,"Clinical Association Between Pharmacogenomics and Adverse Drug Reactions","https://link.springer.com/article/10.1007/s40265-015-0375-0","Imipramine","CYP2D6","pre/post ","Psychiatry","Poor metabolizes have side effects due to high serum concentration of TCA (affects aplpha-1, H1, M1 receptors). Cardiovascular: Orthostatic hypotension, hypertension, tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, ECG changes, precipitation of congestive heart failure, stroke. Psychiatric: Confusional states (especially in the elderly) with hallucinations, disorientation, delusions; anxiety, restlessness, agitation; insomnia and nightmares; hypomania; exacerbation of psychosis. Neurological: Numbness, tingling, paresthesias of extremities; incoordination, ataxia, tremors; peripheral neuropathy; extrapyramidal symptoms; seizures, alterations in EEG patterns; tinnitus. Anticholinergic: Dry mouth, and, rarely, associated sublingual adenitis; blurred vision, disturbances of accommodation, mydriasis; constipation, paralytic ileus; urinary retention, delayed micturition, dilation of the urinary tract. Allergic: Skin rash, petechiae, urticaria, itching, photosensitization; edema (general or of face and tongue); drug fever; cross-sensitivity with desipramine. Hematologic: Bone marrow depression including agranulocytosis; eosiNophilia; purpura; thrombocytopenia. Gastrointestinal: Nausea and vomiting, aNorexia, epigastric distress, diarrhea; peculiar taste, stomatitis, abdominal cramps, black tongue. Endocrine: Gynecomastia in the male; breast enlargement and galactorrhea in the female; increased or decreased libido, impotence; testicular swelling; elevation or depression of blood sugar levels; inappropriate antidiuretic hormone (ADH) secretion syndrome. Other: Jaundice (simulating obstructive); altered liver function; weight gain or loss; perspiration; flushing; urinary frequency; drowsiness, dizziness, weakness and fatigue; headache; parotid swelling; alopecia; proneness to falling. Withdrawal Symptoms: Though Not indicative of addiction, abrupt cessation of treatment after prolonged therapy may produce nausea, headache and malaise. ","CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*12, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41"],
    ["Hui, C.K.M., et al.",2011,"Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.","https://www.ncbi.nlm.nih.gov/pubmed/21348581","Indacaterol","UGT1A1","peri","Pulmonary","No relevant effect of UGT1A1 genotype of indacaterol exposure. AEs: cough, oropharyngeal pain, nasopharyngitis, headache and nausea.","UGT1A1 *28"],
    ["Asensi, V., et al.",2015,"Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=nevirapine+side+effect+pharmacogenetic","Indinavir","UGT1A1","pre/post","Infectious Disease","Enhance unconjugated hyperbilirubinemia and jaundice- due to modified plasma levels of indinavir by UGT1A1*28            ","UGT1A1*28"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Infliximab","FccRIIIA","pre/post","Oncology ","Higher infliximab elimination rate constant leading to a faster infliximab under exposure and relapse of disease","Fc?RIIIA-158V/V"],
    ["Farzan, N., et al.",2017,"Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review.","https://www.ncbi.nlm.nih.gov/pubmed/27790783","Inhaled Corticosteroids","FCER2","pre/post","Pulmonary","3 polymorphisms have elevated IgE levels and increased risk of severe asthma exacerbations in children while on inhaled corticosteroids.","rs7249320: T2206C : rs4996974"],
    ["Kantarjian, H.M., et al.",2017,"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INo-VATE study.","https://www.ncbi.nlm.nih.gov/pubmed/28687420","Inotuzumab Ozogamicin","BCR-ABL1","pre/post","Oncology","T315I mutation causes cross-resistant to most KIs.","BCR-ABL1 T315I: BCR-ABL1 Y253H"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Irinotecan","UGT1A1","pre/post","Oncology","Severe diarrhea, myelosuppression, and neutropenia","UGT1A1*6 (c.211G>A) rs4148323 :  UGT1A1*28 rs8175347"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Irinotecan","ABCD1","pre/post","Oncology","Severe diarrhea, myelosuppression, and neutropenia","ABCB1 c.1236T>C rs1128203 :  ABCB1 haloptype*2 c.1236C>T :  ABCB1 haloptype*2 c.2677G>T/A : ABCB1 haloptype*2  c. 3435C>T"],
    ["Dean, L.",2015,"IriNotecan Therapy and UGT1A1 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK294473/","IriNotecan","UGT1A1","pre/post","Oncology","Neutropenia","UGT1A1 *28/*28"],
    ["Krasowski, M. ",2015,"Current Diagnosis & Treatment : Family Medicine Chapter 49: Pharmacogenomics","http://accessmedicine.mhmedical.com/content.aspx?bookid=1415&sectionid=77060361","Irinotecan","UGT1A1","pre/post","Oncology"," Life-threatening neutropenia , diarrhea ","UGT1A1?28"],
    ["Pirmohamed, M. ",2010,"Pharmacogenetics of adverse drug reactions ","https://www.researchgate.net/profile/Munir_Pirmohamed/publication/40697565_Pharmacogenetics_of_Idiosyncratic_Adverse_Drug_Reactions/links/09e4150fd81a89a128000000.pdf","Irinotecan","UDP-glucoronytransferase","pre","Oncology","UDPGT-1A1 is implicated in irinotecan induced diarrhea and leukopenia","UDP-glucoronytransferase 1A1"],
    ["Rodriguez-Antona, C.,et al.",2014,"PharmacogeNomic biomarkers for personalized cancer treatment","https://onlinelibrary.wiley.com/doi/full/10.1111/joim.12321","Irinotecan","UGT1A1","pre/post","Oncology","Neutropenia- induced by irinotecan and uridine diphosphate glucoroNosyltransferase 1A1 (UGT1A1) variants","UGT1A1 variants"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","IriNotecan","UGT1A1","pre/post","Oncology","Neutropenia","UGT1A1*28"],
    ["Xu, C., et al.",2016,"UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of iriNotecan-based chemotherapy in patients with advanced colorectal cancer","https://link.springer.com/article/10.1007/s00280-016-3057-z","Irinotecan","UGT1A1","peri","Oncology","Increased risk for neutropenia","UGT1A1*28"],
    ["Xu, C., et al.",2016,"UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of iriNotecan-based chemotherapy in patients with advanced colorectal cancer","https://link.springer.com/article/10.1007/s00280-016-3057-z","Irinotecan","UGT1A1","peri","Oncology","Shorter overall survival","UGT1A1*28/*6"],
    ["Ando, Y., et al.",2000,"Polymorphism of UDP GlucuroNosyltransferase Gene and IriNotecan Toxicity: A pharmacogenetic analysis","https://www.ncbi.nlm.nih.gov/pubmed/11156391","Irinotecan","UGT1A1","pre/post ","Oncology","Diarrhea, myelosuppresion","UGT1A*6:UGT1A*27:UGT1A*28"],
    ["Rosenberg, H., et al. ",2015,"Malignant hyperthermia: a review","https://ojrd.biomedcentral.com/articles/10.1186/s13023-015-0310-1","Isoflurane","Nonspecific (Genetic Susceptibility to Malignant Hyperthermia)","intra","Anesthesiology","Malignant hyperthermia","mutations in RYR1: CACNA1S: STAC3: CACNA2D1, Tyrosine 522"],
    ["Chan, S.L., et al.",2017,"Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642896/#pone.0186200.s012","Isoniazid","NAT2","pre","Infectious Disease","Drug-induced liver injury with elevation in serum transaminases; Icteric hepatitis (serum bilirubin > 3.0 mg/dL)"," NAT2 rs1041983 :  NAT2 rs1495741 : NAT2*6/6 : NAT2*6/7 : NAT2*5/*7 "],
    ["Vuilleumier, N., et al.",2006,"CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.","https://www.ncbi.nlm.nih.gov/pubmed/16770646","Isoniazid","CYP2E1","pre","Infectious Disease","Drug-induced liver injury with elevation in serum transaminases"," CYP2E1 *1A/*1A "],
    ["Wang, P., et al.",2016,"Isoniazid metabolism and hepatotoxicity","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045547/","Isoniazid","GSTM1","pre","Infectious Disease","transient transaminase elevation, Drug Induced Liver injury","GSTM1 *0/*0 : GSTT1*0/*0"],
    ["Wilke, R.A., et al.",2007,"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763923/","Isoniazid, Pyrazinamide, and Rifampin","Nonspecific  (NAT): DRB1","pre","Infectious Disease","Drug-induced liver injury with elevation in serum transaminases, Icteric hepatitis","DRB1*03:  Nonspecific  (NAT)"],
    ["Rehman, H.U.",2001,"Evidence-Based Case Review: Methemoglobinemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1071541/","Isosorbide Dinitrate","CYB5R","peri","Cardiology","Methemoglobinemia","CYB5R1: CYB5R2: CYB5R3: CYB5R4 "],
    ["Abad-Pérez, D., et al. ",2013,"Effect of oral nitrates on pulse pressure and arterial elasticity in patients aged over 65 years with refractory isolated systolic hypertension: study protocol for a randomized controlled trial","https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-388","Isosorbide MoNonitrate","CYB5R","peri","Cardiology","Methemoglobinemia","CYB5R1, CYB5R2, CYB5R3, CYB5R4"],
    ["Pettit, R., et al.",2014,"CFTR Modulators for the Treatment of Cystic Fibrosis.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103577/","Ivacaftor","CFTR","pre/post","Pulmonary","Not effective if homozygous for the F508del mutation in the CFTR gene","F508del-CFTR, G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, S549R, G551D."],
    ["Li, Y., et al. ",2013,"The CYP2B6*6 Allele Significantly Alters the N-Demethylation of Ketamine Enantiomers In Vitro","https://www.ncbi.nlm.nih.gov/pubmed/23550066","Ketamine","CYP2B6","intra","Anesthesiology","Drug clearance reduction by significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.","CYP2B6*6"],
    ["Bentué-Ferrer, D., et al.",2012,"Therapeutic drug monitoring of lacosamide","https://www.ncbi.nlm.nih.gov/pubmed/22850102","Lacosamide","CYP2C19","peri","Neurology","plasma concentrations and amount excreted into urine of the O-desmethyl metabolite were about 70% reduced inPoor metabIL compared to EMs. ","CYP2C19*2 : CYP2C19*3."],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Lamotrigine","HLA-B","pre","Neurology","Steven Johnson Syndrome, toxic epidermal necrolysis","HLA-B*3801"],
    ["MacKenzie, M., et al.",2017,"Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review.","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Lansoprazole","CYP2C19","pre/post","Gastroenterology","The blood concentration of tacrolimus in a patient who had a CYP2C19 gene mutation may have been elevated by decreased hepatic elimination of lansoprazol","CYP2C19*2"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Lansoprazole","CYP2C19","pre/post","Gastroenterology","ventilator acquired pneumonia (poor metabolizers). ","CYP2C19*2"],
    ["Miura, M., et al.",2007,"Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients","http://onlinelibrary.wiley.com/doi/10.1002/bdd.544/full","Lansoprazole","CYP2C19 : CYP3A5 : MDR1","pre/post","Gastroenterology","Patients with genetic polymorphisms need lower dosages of tacrolimus to achieve the target therapeutic index.","CYP3A5*3/*3"],
    ["Miura, M., et al.",2005,"Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers","http://www.tandfonline.com/doi/abs/10.1080/00498250500111562","Lansoprazole","CYP2C19","pre/post","Gastroenterology","Renal-transplant recipients who are CYP2C19 extensive metabolizers, there is less stereoselective difference in the pharmacokinetic disposition between the (R)- and (S)-enantiomers of rabeprazole than those of lansoprazole.","-"],
    ["Takahashi, K., et al.",2004,"Lansoprazole—Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism","http://journals.sagepub.com/doi/abs/10.1345/aph.1D366","Lansoprazole","CYP2C19","pre/post","Gastroenterology","The blood concentration of tacrolimus in a patient who had a CYP2C19 gene mutation may have been elevated by decreased hepatic elimination of lansoprazole.","exon 5 of the CYP2C19 gene (CYP2C19*1/*2)"],
    ["Cristofanilli, M., et al.",2013,"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539065/","Lapatinib","ERBB2 (HER2)","pre/post","Oncology","Decreases in Left Ventricular Ejection Fraction, potential cardiac toxicity","ERBB2 Pro1170 Ala polymorphism in HER2-neu"],
    ["Finn, R.S., et al.",2009,"Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unkNown metastatic breast cancer.","https://www.ncbi.nlm.nih.gov/pubmed/19620495","Lapatinib","ESR, PGR ","pre/post","Oncology","ESR1 PvuII, was associated with increased risk of breast cancer and decreased ER expression","ESR1 PvuIl: , PGR (Hormone Receptor)"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Lapatinib","DRB1: DQA1","pre/post","Oncology","DILI drug-induced liver injury","DRB1*07:01, DQA1*02:01"],
    ["Pirmohamed, M.",2014,"Personalized Pharmacogenomics: predicting Efficacy and Adverse Drug Reactions","http://www.annualreviews.org/doi/full/10.1146/annurev-geNom-090413-025419#_i28","Lapatinib","HLA-DQA1: HLA-DRB1","pre/post","Oncology","HLA alleles DQA1*02:01 and DRB1*07:01 carriers had incidence of severe liver injury of 8% versus 0.5% in Non-carriers.","HLA DQA1*02:01:    HLADRB1*07:01 "],
    ["Dean, L. ",2017,"Sofosbuvir Therapy and IFNL4 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK409960/","Ledipasvir","IFNL3 (IL28B)","peri","Infectious Disease","Homozygosity for the rs12979860-C allele (IL28B-CC genotype) assoc. w/faster viral kinetic (VK) decline and higher odds of achieving SVR with IFN-?/RBV therapy. The genetic variant rs12979860, located in the INFL4 gene, is a strong predictor of response to peginterferon-based therapies. The variant is a C to T change—individuals with the favorable “C/C” genotype have about a 2-fold higher likelihood of achieving SVR compared to individuals with CT or TT genotypes","The rs12979860 allele is located in the INFL4 gene. The variant is a C to T change. Individuals can have  IL28B-CC, IL28B-CT or IL28B-TT genotypes"],
    ["List, A., et al.",2006,"Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion","http://www.nejm.org/doi/full/10.1056/NEJMoa061292#t=article","Lenalidomide","Chromosome 5q","pre/post","Hematology","EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENoUS and ARTERIAL THROMBOEMBOLISM Hematologic Toxicity (Neutropenia and Thrombocytopenia) REVLIMID- neutropenia and thrombocytopenia. AE related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, GI disorders, and general disorders and administrative site conditions","Chromosome 5q"],
    ["Gupta, A., et al.",2016,"Lesinurad: A significant advancement or just aNother addition to existing therapies of gout?","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242027/","Lesinurad","CYP2C9","pre/post","Rheumatology","Lesinurad exposure is increased","CYP2C9 *2: CYP2C9 *3"],
    ["Krainick-Strobel, U.E., et al.",2008,"Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.","https://www.ncbi.nlm.nih.gov/pubmed/18302747","Letrozole","ESR, PGR","post","Oncology","Hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain; and musculoskeletal","ESR, PGR (Hormone Receptor)"],
    ["Barash, M., et al.",2015,"Lidocaine-Induced Methemoglobinemia: A Clinical Reminder","http://jaoa.org/article.aspx?articleid=2211844","Lidocaine","CYB5R3","peri","Anesthesiology","The soluble isoform of cytochrome b5 reductase 3 changes ferric iron back to ferrous iron so hemoglobin can function. G6PD deficiency or congenital or idiopathic methemoglobinemia more susceptible to drug?induced methemoglobinemia.","CYB5R3 gene mutations"],
    ["Elyassi, C.A.R., et al.",2009,"Perioperative Management of the Glucose-6-Phosphate Dehydrogenase Deficient Patient: A Review of Literature","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749581/","Lidocaine","G6PD","peri","Anesthesiology","Glucose?6?phosphate dehydrogenase deficiencies and pts taking oxidizing drugs (antimalarials and sulfonamides) more susceptible to drug?induced methemoglobinemia.","G6PD, glucose?6?phosphate dehydrogenase deficiencies "],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Lovastatin","CYP3A5","pre/post","Cardiology","Higher LDL cholesterol levels due to decreased efficacy","CYP3A5*1 c.6986A>G rs776746"],
    ["Marsicano, A.R., et al.B271",1973,"Fatal hemolysis from mafenide treatment of burns in a patient with glucose-6-phosphate dehydrogenase deficiency. Case report.","https://www.ncbi.nlm.nih.gov/pubmed/4722683","Mafenide","G6PD","intrapost","Infectious Disease","Fatal hemolytic anemia with disseminated intravascular coagulation","G6PD, glucose-6-phosphate dehydrogenase deficiency"],
    ["Goldstein, J.A.",2001,"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","http://onlinelibrary.wiley.com/doi/10.1046/j.0306-5251.2001.01499.x/full","Mephenytoin","CYP2C19","pre/post","Neurology","Poor metabolisers of drug can experience toxicity.","Poor metabolizer genotype"],
    ["Evans, W.E.",2001,"preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine","http://ascopubs.org/doi/abs/10.1200/JCO.2001.19.8.2293","Mercaptopurine","TPMT","pre/post","Oncology","Azathioprine :PM have higher rates of profound bone marrow toxicity; 6-MP: PM have higher rates of profound bone marrow toxicity/ suppression. Genetic polymorphisms and loss of function of TPMT (thiopurine S-methyltransferase) results and severe and life threatening hematopoietic toxicity","genetic polymorphisms and loss of function of TPMT (thiopurine S-methyltransferase) "],
    ["Dujic, T., et al.",2016,"Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study.","https://www.ncbi.nlm.nih.gov/pubmed/?term=biguanid+side+effect+gene+polymorphism","Metformin","OCT1:SERT","pre/post","Endocrinology","Gastrointestinal intolerance to metformin due to OCT1 and SERT gene polymorphisms. ","SERT 5-HTTLPR/rs25531 L*L*: 0 or 1 deficient allele carriers of OCT1"],
    ["Shu, Y., et al.",2007,"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857259/","Metformin","OTC1","pre/post","Endocrinology","Impaired glucose absorption and control","OCT1 R61C : OCT1  G410S : OCT1  420del : OCT1 G465R"],
    ["Kharasch, E.D.",2015,"Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance and metabolism","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667947/","Methadone","CYP2B6","intrapost","Anesthesiology","CYP2B6 genotype affects methadone plasma concentrations, clearance, and metabolism. CYP2B6*6 allows for higher methadone plasma concentrations and low methadone clearance.","CYP2B6*6"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Methazolamide","HLA-B","pre","Ophthalmology","Steven Johnson Syndrome, toxic epidermal necrolysis","HLA-B*5901 "],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Methotrexate","ARID5B : ABCB1 : MTHFR : SLCO1B1 : SLC19A1","pre/post","Oncology","Stomatitis, malaise, nausea, diarrhea, headaches and mild alopecia, hepatic, renal, pulmonary and bone marrow disorders","ABCC2 c.1234A>G rs765027508 : MTHFR c.665C>T  C677T : MTHFR c.1286A>C rs1801133  rs1801131 :  ARID5B c.1200-6044T>C  rs4948502 : ARID5B c.734-5030T>C  rs4948496 : ARID5B c.276+7693C>A  rs4948487"],
    ["Kishi, S., et al.",2017,"Ancestry and pharmacogenetics of antileukemic drug toxicity","https://pdfs.semanticscholar.org/7a0a/f6dc3eb077be52e8f1d5a0e9178d9e3afd93.pdf","Methotrexate","UGT1A1","pre/post ","Oncology","Hyperbilirubinemia, neurotoxicity","RFC 80A"],
    ["Lopez-Lopez, E., et al.",2011,"Polymorphisms of the SLCO1B1 Gene Predict Methotrexate-Related Toxicity in Childhood Acute Lymphoblastic Leukemia","https://www.ncbi.nlm.nih.gov/pubmed/21387541","Methotrexate","RFC1","pre/post","Oncology","Gastrointestinal, hepatic toxicity","G80A"],
    ["Vujkovic, M., et al.",2015,"Association between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621538/","Methotrexate","TPMT:MTHFR:MTR","pre/post","Oncology","Risk of relapse after pediatric ALL treatment ","rs2842947:rs1801131:rs1801133:rs10925235:rs1805088"],
    ["Relling, M.V., et al.",2004,"Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia","https://www.ncbi.nlm.nih.gov/pubmed/15459215","Methotrexate","TYMS ","pre/post ","Oncology","Osteonecrosis ","TYMS 2/2"],
    ["Qiu, Q., et al.",2017,"Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.","https://www.ncbi.nlm.nih.gov/pubmed/28296761","Methotrexate","RFC-1","pre/post","Oncology","Gastrointestinal, hepatic toxicity ","rs1051266"],
    ["Sikka, P., et al.",2011,"Blue cures blue but be cautious","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249703/","Methylene Blue","G6PD","intra","Hematology","severe hemolysis and severe anemia risk for G6PD deficiency. contraindicated in pts w/ glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of hemolytic anemia","glucose-6-phosphate dehydrogenase deficiency (G6PD) "],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Methylene blue","G6PD deficiency","pre/post","Infectious Disease","acute hemolytic anemia due to G6PD deficiency","G6PD  "],
    ["Karadsheh, N.S., et al.",2001,"Metoclopramide-induced methemoglobinemia in a patient with co-existing deficiency of glucose-6-phosphate dehydrogenase and NADH-cytochrome b5 reductase: failure of methylene blue treatment.","https://www.ncbi.nlm.nih.gov/pubmed/11418378","Metoclopramide","CYB5R","peri","Gastroenterology","Methemoglobinemia","CYB5R1: CYB5R2: CYB5R3: CYB5R4"],
    ["Özmen, I, et al.",2004,"Effects of antiemetic drugs on glucose 6-phosphate dehydrogenase and some antioxidant enzymes.","https://www.ncbi.nlm.nih.gov/pubmed/15458770","Metoclopramide","G6PD","peri","Gastroenterology","Methemoglobinemia","glucose?6?phosphate dehydrogenase deficiencies"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Metoprolol","CYP2D6","peri","Cardiology","Bradyarrythmia and heart failure in poor metabolizers","CYP2D6*3: CYP2D6*4: CYP2D6*5: CYP2D6*6"],
    ["MacKenzie, M., et al.",2017,"Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review.","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Metoprolol","CYP2D6","peri","Cardiology","Tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash.","CYP2D6 *3, *4, *5, *6, *7, *8, *11, *12, *13, *14, *15, *16, *18, *19, *20, *21, *38, *40, *42, *44, *56 and *62 "],
    ["Lymperopoulos, A., et al.",2015,"Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.","https://www.ncbi.nlm.nih.gov/pubmed/26537419","Metropolol","CYP2D6","peri","Cardiology","Bradycardia, hypotension,decreased therapeutic effect. ","CYP2D6*1:  CYP2D6*2 : CYP2D6*3 : CYP2D6*4 : CYP2D6*5 : CYP2D6*6 :  CYP2D6*9 : CYP2D6*10 : CYP2D6*17 : CYP2D6*41 : CYP2D6*1XN : CYP2D6*2XN"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Midazolam","CYP3A4","pre","Anesthesiology","Reduced metabolism leading to increased sedation in poor metabolizer","CYP3A4*3"],
    ["De Kouchkovsky, I., et al.",2016,"Acute myeloid leukemia: a comprehensive review and 2016 update","http://www.nature.com/bcj/journal/v6/n7/full/bcj201650a.html?foxtrotcallback=true","Midostaurin","NPM1","pre/post","Oncology","AML: The most common adverse effect (AEs) were febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, and upper respiratory tract infection. ASM, SM-AHN, or MCL: most common AEs were nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, pyrexia, headache, and dyspnea.","NPM1 mutations"],
    ["Jawhar, M., et al. ",2017,"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.","https://www.ncbi.nlm.nih.gov/pubmed/28424161","Midostaurin","KIT","pre/post","Oncology","AML: The most common AEs were febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, and upper respiratory tract infection. ASM, SM-AHN, or MCL: most common AEs were nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, pyrexia, headache, and dyspnea.","KIT D816V mutation"],
    ["Levis, M.",2017,"Midostaurin approved for FLT3-mutated AML","http://www.bloodjournal.org/content/bloodjournal/129/26/3403.full.pdf","Midostaurin","FLT3","pre/post","Oncology","Febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, and upper respiratory tract infection.","FLT3-mutated AML"],
    ["Bondy, B., et al.",2004,"Pharmacogenetics and psychopharmacology","https://www.sciencedirect.com/science/article/pii/S1471489203001875","Modafinil","CYP2D6","pre","Psychiatry","Reversibly inhibits CYP2C19 leading to potential interaction with drugs such as diazepam, propraNolol, phenytoin, and TCAs which are metabolized by this enzyme.","CYP2D6?4 : CYP2D6 ?10 : CYP2D6 ?14"],
    ["Crews, K.R., et al.",2014,"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.","https://www.ncbi.nlm.nih.gov/pubmed/24458010","Morphine","CYP2D6","post","Anesthesiology","Toxic systemic concentrations of morphine, which increases the risk of morphie adverse reactions (eg. Respiratory depression, shock, respiratory arrest, cardiac arrest, and circulatory depression) due to extensive or ultrarapid CYP2D6 metabolizers. Meanwhile, there's reduced morphine formation in intermediate and poormetabolizers,which lead to insufficient pain relief.","CYP2D6 *1/*1xN, *1/*2xN(ultrarapid metabolizer): CYP2D6 *1/*1, *1/*2, *2/*2, *1/*41, *1/*4, *2/*5, *1/*10 (extensive metabolizer): CYP2D6 *4/*10, *5/*41 (intermediate metabolizer): CYP2D6 *4/*4, *4/*5, *5/*5, *4/*6 (poor metabolizer)"],
    ["Venkatasubramanian, R.",2014,"ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190075/","Morphine","ABCC3 : OCT1","intrapost","Anesthesiology ","OCT1 homozygous genotypes are associated with lower morphine CL in this extended cohort; well supported by corresponding observations of lower morphine glucuronide formation. In addition, it shows that children with the ABCC3 ?211C>T poly morphism C/C genotype have significantly higher (~40%) metabolite transformation than C/T+T/T genotypes.","ABCC3 ?211C : OCT1*2–*5"],
    ["Sadhasivam, S., et al.",2015,"Novel Associations between FAAH Genetic Variants and postoperative Central Opioid related Adverse Effects","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492912/","Morphine","FAAH","intrapost","Anesthesiology ","Refractory post-op nausea and vomiting, opioid-related respiratory depression","FAAH rs4141964:  FAAH rs3766246 : FAAH rs324420 : FAAH rs2295632 : FAAH kgp12517369"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Morphine","UGT2B7","intrapost","neurology","Reduced metabolism leading to Increased incidence of nausea in poor metabolizer","UGT2B7*2"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Morphine","A118A/G","intrapost","neurology","Reduced analgesic effect and less postoperative nausea and vomiting in subjects with AG or GG alleles","A118A/G"],
    ["Ji, Y.S., et al.",2006,"Regulation of the Interaction of Inosine Monophosphate Dehydrogenase with Mycophenolic Acid by GTP","http://www.jbc.org/content/281/1/206.full","Mycophenolic Acid","HPRT1","post","Oncology","overproduction and accumulation of uric acid. acute arthritis, tophi, nephrolithiasis or urolithiasis and renal disease including renal failure. Mutations in HPRT1 gene result in Lesch-Nyhan syndrome or gout.","Hereditary deficiency of HGPRT"],
    ["Youngster, I., et al.",2010,"Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.","https://www.ncbi.nlm.nih.gov/pubmed/20701405","Nalidixic Acid","G6PD","peri","Infectious Disease","tendon rupture, cholestasis, paresthesia, metabolic acidosis, thrombocytopenia, leukopenia, or hemolytic anemia, sometimes associated with glucose 6- phosphate dehydrogenase deficiency and peripheral neuropathy.","G6PD deficiency due to mutation in the G6PD gene."],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Nelfinavir","CYP2C19","pre/post","Infectious Disease","Trend towards decreased virologic failure - CYP2C19*2 allele can influence the bioavailability of nelfinavir. ","CYP2C19*2"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Nevirapine","HLA-Cw8","pre","Infectious Disease","delayed-type hypersensitivity reaction","HLA-Cw8-B14"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Nevirapine","HLA-B","pre","Infectious Disease","delayed-type hypersensitivity reaction","HLA-B*3505"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Nevirapine","HLA-DRB","pre","Infectious Disease","delayed-type hypersensitivity reaction","HLA-DRB1*0101 "],
    ["Asensi, V., et al.",2015,"Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=nevirapine+side+effect+pharmacogenetic","Nevirapine","HALDRB","pre/post","Infectious Disease","Nevirapine-induced hypersensitivity and hepatotoxicity - due to HALDRB*0101 polymorphism in HIV patients receivig nevirapine. HLA-cw8 mutation showed increased hypersensitivity in Italian and Japanese polpulations. CYP2B6983T>C(SNP28399499) polymorphism showed increased risk of hypersensitivity in Malawian and Ugandan populations.","HALDRB*0101:HLA-cw8:CYP2B6983T>C(SNP28399499)"],
    ["Singer, J.B.",2007,"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.","https://www.ncbi.nlm.nih.gov/pubmed/17611564","Nilotinib","UGT1A1","pre/post","Oncology","Hyperbilirubinemia","UGT1A1*28"],
    ["Zabriskie, M.S., et al.",2014,"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160372/","Nilotinib","BCR-ABL1","pre/post","Oncology","Relapse of disease- Mutations in BCR-ABL1 may confer resistance and treatment failure leading to disease progression. T315I mutants are also found to confer high-level resistance to Tyrosine Kinase Inhibitors.","BCR-ABL1:M244, G250, Q252, Y253, E255, V299, F311, T315, F317, M351, F359, and H396:T315I"],
    ["Ormerod, J., et al.",2017,"endothelial dysfunction- Homozygous ALDH2*2 was neither stimulated Nor inhibited by nitrite, therefore did Not display protection for endothelial damage when compared to ALDH2*1 or Heterozygous ALDH2*2 ","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329169/","Nitrite","ALDH2","intra","Cardiology ","Endothelial dysfunction","ALDH2*2"],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Nitrofurantoin","G6PD deficiency","pre/post","Infectious Disease","acute hemolytic anemia due to G6PD deficiency","G6PD "],
    ["Lavelle, K.J.",2006,"Hyperlactatemia and hemolysis in G6PD deficiency after nitrofurantoin ingestion.","http://europepmc.org/abstract/med/12659","Nitrofurantoin","G6PD","intrapost","Infectious Disease","Hyperlactatemia and Hemolysis in susceptible subjects and hepatocellular injury.","G6PD deficiency"],
    ["Nagele, P., et al.",2008,"Influence of Methylenetetrahydrofolate Reductase Gene Polymorphisms on Homocysteine Concentrations after Nitrous Oxide Anesthesia","http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1922603","Nitrous Oxide","MTHFR","intra","Anesthesiology","Nitrous oxide administration with an undelying MTHFR mutation caused an induced hyperhomocysteinemia and inhibition of folate metabolism which lead to apoptosis, megaloblastic anemia, bone marrow disorders, myelopathy, peripheral neuropathy, hemiparesis, death ","MTHFR 677C>T:MTHFR 1298A>C"],
    ["Selzer R., et al.",2003,"Adverse Effect of Nitrous Oxide in a Child with 5,10-Methylenetetrahydrofolate Reductase Deficiency","https://www.nejm.org/doi/full/10.1056/NEJMoa021867","Nitrous Oxide","MTHFR","peri","Anesthesiology","Neurologic deterioration and death","MTHFR mutation (1755G?A) : MTHFR polymorphisms (677C?T and 1298A?C: "],
    ["Nomizo, T., et al.",2017,"Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362817/","nivolumab","PD-L1","pre/post","Oncology","Decreased response to drug and decreased mean survival","PD-L1 rs4143815 G/G : PD-L1 rs2282055 T/T"],
    ["Hicks, J.K., et al.",2013,"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226/","Nortriptyline","CYP2D6 : CYP2C19","pre","Psychiatry","Coma, respiratory depression, tachycardia, QRS prolongation, decreased cardiac contractility , decreased GI motility, torsades de pointes","CYP2D6*1:  CYP2D6*2 : CYP2D6*3 : CYP2D6*4 : CYP2D6*5 : CYP2D6*6 :  CYP2D6*9 : CYP2D6*10 :  CYP2D6*1XN : CYP2D6*2XN : CYP2C19*1 : CYP2C19*2 : CYP2C19*3 : CYP2C19*17 "],
    ["Tobinai, K.",2016,"A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331088/","Obinutuzumab","MS4A1","pre/post","Oncology","Decreased response to treatment","V158/V158 or F158/F158 Fc?RIIIa receptor"],
    ["Bigos, K., et al.",2011," Genetic Variation in CYP3A43 Explains Racial Difference in Olanzapine Clearance","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100476/","Olanzapine","CYP 3A4","pre/post","Psychiatry"," Higher prevalence of positive symptoms.","CYP3A43 rs472660"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Olanzapine","CYP2D6","peri","Psychiatry","Increased sedation in poor metabolizers","CYP2D6*3: CYP2D6*4: CYP2D6*5: CYP2D6*6"],
    ["Teyssonneau, D., et al.",2017,"Olaratumab for Soft Tissue Sarcoma","https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1339031","Olaratumab","PDGFRA","pre/post","Oncology","Anemia and Neutropenia","PDGFR-alpha"],
    ["Chen, Y.",2014,"Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia","https://www.ncbi.nlm.nih.gov/pubmed/24516334","Omacetaxine","BCR-ABL","pre/post","Oncology","Decreased response to treatment","BCR-ABL-T315I"],
    ["Michael, S., et al. ",2015,"Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.","https://www.ncbi.nlm.nih.gov/pubmed/26622169","Ombitasvir","IFNL3 ","intrapost","Infectious Disease","Decreases response to treatment","IL-28B"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Omeprazole","CYP2C19","pre/post","Gastroenterology","ventilator acquired pneumonia (poor metabolizers). Omeprazole: Reports of decreases in cure rates at low dosage in homozygous or heterozygous EMs ","CYP2C19*2"],
    ["Goldstein, J.A.",2001,"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","http://onlinelibrary.wiley.com/doi/10.1046/j.0306-5251.2001.01499.x/full","Omeprazole","CYP2C19","pre/post","Gastroenterology","Poor metabolisers of drug can experience toxicity.","Poor metabolizer genotype"],
    ["Ando, T., et al. ",2005,"A Comparative Study on Endoscopic Ulcer Healing of Omeprazole Versus Rabeprazole with Respect to CYP2C19 GeNotypic Differences","https://link.springer.com/article/10.1007%2Fs10620-005-2907-z?LI=true","Omeprazole Versus","CYP2C19","pre/post","Gastroenterology","effect on ulcer healing","-"],
    ["Behrooz, A.",2015,"Pharmacogenetics and anaesthetic drugs: Implications for perioperative practice","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685230/","Ondansetron","ABCB1","post ","Gastroenterology","Individuals with two of these variants, the CG haplotype (C3435T and G2677T) were more likely to experience chemotherapy induced nausea and vomiting despite receiving ondansetron. CG haplotype was associated with greater ABCB1 expression, those individuals might have a decrease in levels of CNS accumulation of ondansetron ","C3435T : G2677T"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Ondansetron","CYP2D6","post","Gastroenterology","Increased nausea and vomiting in Ultra Metabolizers. ABCB1 gene polymorphisms are associated with antiemetic efficacy of ondansetron in the acute phase after high-dose cytarabine chemotherapy in AML patients.        C3435T and G2677T","CYP2D6*3: CYP2D6*4: CYP2D6*5"],
    ["He, H.",2014,"Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.","https://www.ncbi.nlm.nih.gov/pubmed/25012726","Ondansetron","ABCB1","post","Oncology","ABCB1 gene polymorphisms are associated with variation of antiemetic efficacy of ondansetron.","C3435T :G2677T"],
    ["Odogwu, L.",2017,"FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation","https://www.ncbi.nlm.nih.gov/pubmed/29242281","Osimertinib","EGFR","pre/post","Oncology","ILD/pneumonitis, prolonged QTc interval, or decrease in cardiac contractility","EGFR T790M "],
    ["Inada, M., et al.",2010,"Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes","https://www.ncbi.nlm.nih.gov/pubmed/20979931","Oxaliplatin","ERCC1:GSTP1","pre/post","Oncology","Grade 1 chronic neuropathy was found to be induced earlier in those who had ERCC1(C118T) and GSTP1(Ile105Val) polymorphisms.  Polymorphisms are shown cause an increased sensitivity to neuropathy in these patients.","ERCC1(C118T)C/T,T/T>C/C:GSTP1(Ile105Val)"],
    ["Chen, Y.",2008,"Oxcarbazepine-induced Stevens–Johnson syndrome in a patient with HLA-B*1502genotype","http://onlinelibrary.wiley.com/doi/10.1111/j.1468-3083.2008.02988.x/full","Oxcarbazepine","HLA-B","post","Neurology","Steven Johnson","HLA-B*1502"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Oxcarbazepine","HLA-B","peri","Neurology ","DRESS, MPE, SJS/TEN","HLA-B*15:02"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Oxicams","HLA-B","pre/post","Rheumatology","Steven Johnson Syndrome, toxic epidermal necrolysis","HLA-B*7301 "],
    ["Samer, C.F., et al.",2011,"Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935998/","Oxycodone","CYP2D6","post","Anesthesiology","Polymorphisms in CYP2D6 lead to higher concentration of active metabolities leading to toxicities. CYP2D6 under metabolizers are also at increased risk of a drug-drug itneraction with a CYP3A inhibitor.","CYP2D6*5/*35 :  CYP2D6*41/*41xN :  CYP2D6*1/*41:  CYP2D6*5/*41 :  CYP2D6*4/*35 :  CYP2D6*2/*41 :  CYP2D6*1/*4 : CYP2D6*1/*2xN :  CYP2D6*1/*6 :  CYP2D6*4/*4 "],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Oxycodone","CYP2D6","post","Psychiatry","Increased analgesia and sedative effect because of higher concentration of active metabolities leading to toxicities.","CYP2D6*3: CYP2D6*4: CYP2D6*5: CYP2D6*6"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Paclitaxel","ABCB1","pre/post","Oncology","Neurotoxicity and peripheral neuropathy","ABCB1 c.1236T>C  rs1128203 : ABCB1 c.2677T>A/G rs2032582"],
    ["Rodriguez-Antona, C.,et al.",2014,"PharmacogeNomic biomarkers for personalized cancer treatment","http://onlinelibrary.wiley.com/doi/10.1111/joim.12321/full","Paclitaxel","CYP3A4","pre/post","Oncology","High risk of severe neuropathy with patients that carry loss-of-function CYP3A4 alleles and use paclitaxel.","CYP3A*20 (rs67666821)"],
    ["Lynce, F.",2017,"A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer","http://cancerres.aacrjournals.org/content/77/4_Supplement/OT2-01-09.short","Palbociclib","HER-2/ESR","pre/post","Oncology","Neutropenia and Leucopenia","HER-2 Noncodified polymorphism"],
    ["Ane, J.",2014,"Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients","http://onlinelibrary.wiley.com/doi/10.1111/exd.12510/full","Panitumumab","EGFR/RAS","pre/post","Oncology","Skin Rash","Four EGFR polymorphisms (?216, ?191, CA-SSR, R521K)"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Pantoprazole","CYP2C19","pre/post","Gastroenterology","ventilator acquired pneumonia (poor metabolizers).","CYP2C19*2"],
    ["Gex-Fabry, M.",2008,"CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response","http://journals.lww.com/drug-monitoring/Abstract/2008/08000/CYP2D6_and_ABCB1_Genetic_Variability__Influence_on.11.aspx","Paroxetine","CYP2D6 : ABCB1","pre/post","Psychiatry","Influence on plasma levels and therapeutic response","CYP2D6 *3: *4: *5: *6:*xN : ABCB161A>G: 2677G>T: 3435C>T"],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Pazopanib","HLA-B","pre/post","Oncology","DILI drug-induced liver injury","HLA-B*57:01"],
    ["Relling, M.V.",2014,"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype","http://onlinelibrary.wiley.com/doi/10.1038/clpt.2014.97/full","Pegloticase","G6PD","post","Rheumatology","Acute Hemolytic anemia and methemoglobinemia.","G6PD deficiency"],
    ["Wu, J.",2017,"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341153/","Pembrolizumab","BRAF : CD274 ","pre/post","Oncology","Immune-mediated pneumonitis may be associated with autoimmune process","PD-1.1 G/A and PD-1.3 GA"],
    ["Jerling, M.",1996,"The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol","http://onlinelibrary.wiley.com/doi/10.1016/S0009-9236(96)90111-3/full","Perfenazine","CYP2D6","pre/post","Psychiatry","Alteration to oral clearance","CYP2D6 poor metabolizers "],
    ["Gianni, L",2012,"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.","https://www.ncbi.nlm.nih.gov/pubmed/22153890","Pertuzumab","ERBB2 ","pre/post","Oncology","Neutropenia and Leucopenia","ERBB2"],
    ["Gianni, L",2012,"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.","https://www.ncbi.nlm.nih.gov/pubmed/22153890","Pertuzumab","ESR : PGR ","pre/post","Oncology","Neutropenia and Leucopenia","any polymorphism wont allow the antibody to attach to the receptor."],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Phenazopyridine","G6PD deficiency","intra","Anesthesiology","Acute hemolytic anemia due to G6PD deficiency","G6PD  "],
    ["Illing, P.T., et al.",2017,"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","https://www.ncbi.nlm.nih.gov/pubmed/28695285","Phenytoin","HLA-B","pre","Neurology","SJS/TEN. pts w/ HLA-B*15:02 variant kNown to be susceptible to phenytoin-induced SJS/TEN","HLA-B*15:02 "],
    ["Krasowski, M. ",2015,"Current Diagnosis & Treatment : Family Medicine Chapter 49: Pharmacogenomics","http://accessmedicine.mhmedical.com/content.aspx?bookid=1415&sectionid=77060358","Phenytoin","HLA-B","pre","Neurology","Steven-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome","HLA-B*1502"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Phenytoin","CYP2C9: CYP2C19","pre","Neurology","toxic symptoms caused by excessive phenytoin levels at a ‘lower than standard’ dosage in a patient carrying the polymlrphisms.","CYP2C9*2: CYP2C9*3: CYP2C19*2"],
    ["Saruwatari, J., et al. ",2010,"The clinical impact of cytochrome P450 polymorphisms on anti-epileptic drug therapy","https://www.jstage.jst.go.jp/article/eands/3/1/3_1_34/_pdf","Phenytoin","CYP2C9 : CYP2C19","pre","Neurology","Steven Johnson Syndrome, toxic epidermal necrolysis","CYP2C9*2 :  CYP2C9*3 :  CYP2C19*2 : CYP2C19*3"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Phenytoin","HLA-B","pre","Neurology","Steven Johnson Syndrome, toxic epidermal necrolysis","HLA-B*1502"],
    ["Caudle, K.E., et al.",2014,"Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206662/","Phenytonin","HLA-B:CYP2C9","pre/post","Neurology","Increased risk of Hematologic toxicity, hepatic toxicity, leukopenia, pancytopenia, Steven Johnson Syndrome, and Toxic Epidermal Necrolysis - Due to HLA-B*15:02 polymorphism, reduced phenytonin metabolism will increase its plasma concentration which will increase the chance of toxicities. Increased risk of Cerebellar atrophy, Steven Johnson Syndrome, and Toxic Epidermal Necrolysis- Phenytoin toxicity is further increased due to the reduced function of the alleles of CYP2C9, this leads to a decrease in enzyme function and consequently decreased phenytoin metabolism. If both HLA?B*15:02 and CYP2C9 genotypes are present, the risk for adverse effect is further increased.","HLA-B*15:02:CYP2C9*2:CYP2C9*3"],
    ["Eum, S., et al.",2016,"Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067149/","Pimozide","CYP2D6","pre/post","Psychiatry","prolongation of the QT interval","CYP2D6*9 :  CYP2D6 *10 :  CYP2D6*17 :  CYP2D6 *29 :  CYP2D6 *36 :  CYP2D6  *41 "],
    ["Preskorn, S., et al.",2012,"Changes in the Product Label for Pimozide Illustrate Both the Promises and the Challenges of Personalized Medicine","http://www.psychiatrist.com/jcp/article/Pages/2012/v73n09/v73n0907.aspx","Pimozide","CYP2D6","pre/post","Psychiatry","QT-prolongation, fatal ventricular arrhythmias (such as torsades de pointes)- Higher systemic concentrations of pimozide are developed by CYP2D6 poor metabolizers. Since pimozide inhibits potassium channels, the repoarization of myocytes is greatky affected by poor metabolizers.  ","CYP2D6 Poor Metabolizers"],
    ["Jaja, C., et al.",2015,"Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522406/","Piroxicam","CYP2C8:CYP2C9","pre/post","Rheumatology","Gastrointestinal toxicity, gastric bleeding, gastroduodenal bleeding- NSAID therapeutic failure or decreased pain management due to decreased or null enzyme metabolism. ","CYP2C9*2:CYP2C9*3:CYP2C8*3:CYP2C9*1/*3:CYP2C9*1/*2 genotypes"],
    ["Zabriskie, M.S., et al.",2014,"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160372/","Ponatinib","BCR-ABL1","pre/post","Oncology","Relapse of disease- Mutations in BCR-ABL1 may confer pronatinib resistance and treatment failure leading to disease progression. T315I mutants are also found to confer high-level resistance to pronatinib and other Tyrosine Kinase Inhibitors.","BCR-ABL1M244:BCR-ABL1G250:BCR-ABL1Q252:BCR-ABL1Y253:BCR-ABL1E255:BCR-ABL1V299:BCR-ABL1F311:BCR-ABL1F311:BCR-ABL1T315:BCR-ABL1F317:BCR-ABL1M351:BCR-ABL1F359:BCR-ABL1H396: Y253H/E255V, E255V/V299L and F317L/F359V, E255V/T315I, T315I/F359C, T315I/F359V, Y253H/T315I, Y253H/T315I, T315I/H396R, T315I/E453K "],
    ["Ward, R., et al.",2013,"Proton Pump Inhibitors in Pediatrics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616221/","PPIs: Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, Rabeprazole","CYP2C19 : CYP3A5","pre/post","Gastroenterology"," increased risk of C.difficile infections and osteoporosis-related fractures.","CYP2C19*17: CYP3A5*3"],
    ["Ahmed, S., et al.",2016,"Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to precision Medicine","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093856/","Pravastatin","OATPC","pre/post","Cardiology","Myopathy","OATPC*5 , OATPC*9"],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Pravastatin","SLCO1B1","pre/post","Cardiology","Myotocxicity","SLCO1B1*5 : SLCO1B1*15"],
    ["Hoosain, N., et al.",2016,"Mapping SLCO1B1 Genetic Variation for Global precision Medicine in Understudied Regions in Africa: A Focus on Zulu and Cape Admixed Populations.","https://www.ncbi.nlm.nih.gov/pubmed/27631194","Pravastatin","OATP1B3","pre/post","Cardiology","Myopathy","OATP1B1*5 RS4149056C : OATP1B1*15 RS4149056T "],
    ["Cheok, M., et al.",2009,"Pharmacogenetics in Acute Lymphoblastic Leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2665795/","Prednisone","CNTNAP2:LEPR:CRHR1:NTAN1:SLC12A3:ALPL:BGLAP:APOB","peri","Cardiology","Hypertension in children with ALL",""],
    ["Barash, M., et al.",2015,"Lidocaine-Induced Methemoglobinemia: A Clinical Reminder","http://jaoa.org/article.aspx?articleid=2211844","Prilocaine","G6PD","peri","Anesthesiology","G6PD deficiency or congenital or idiopathic methemoglobinemia more susceptible to drug?induced methemoglobinemia.","CYB5R3 gene mutations"],
    ["Elyassi, C.A.R., et al.",2009,"Perioperative Management of the Glucose-6-Phosphate Dehydrogenase Deficient Patient: A Review of Literature","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749581/","Prilocaine","G6PD","peri","Anesthesiology","glucose?6?phosphate dehydrogenase deficiencies and pts taking oxidizing drugs (antimalarials and sulfonamides) more susceptible to drug?induced methemoglobinemia.","G6PD, glucose?6?phosphate dehydrogenase deficiencies "],
    ["Baird, K.",2015,"Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455359/","Primaquine","G6PD","pre/post","Infectious Disease","acute haemolitic anemia, dark urine, death- primaquine increases the risk for mild to severe anaemia when there is G6PD deficiency. ","G6PD deficiency "],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Primaquine","G6PD deficiency","pre/post","Infectious Disease","acute hemolytic anemia due to G6PD deficiency","G6PD "],
    ["Pirmohamed, M. ",2010,"Pharmacogenetics of adverse drug reactions ","https://www.researchgate.net/profile/Munir_Pirmohamed/publication/40697565_Pharmacogenetics_of_Idiosyncratic_Adverse_Drug_Reactions/links/09e4150fd81a89a128000000.pdf","Primaquine","Glucose-6-phosphate dehydrogenase","pre/post","Infectious Disease","G6PD is implicated in primaquine hemolytic anemia","Glucose-6-phosphate dehydrogenase deficiency"],
    ["Zanger, U., et al.",2013,"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.","https://www.sciencedirect.com/science/article/pii/S0163725813000065","proguanil","CYP2C19","pre/post","Infectious Disease","? clearance & ? risk of ADRs for antimalarials (proguanil)","CYP2C19*3"],
    ["Leung, N., et al.",2009,"Acute Kidney Injury in Patients with Inactive Cytochrome P450 Polymorphisms","https://www.ncbi.nlm.nih.gov/pubmed/19814645","Promethazine","CYP2D6","peri","Anesthesiology","Acute kidney injury, and CYP2D6 poor metabolizers exhibit greater sedation for a given promethazine dose.","CYP2C9*3:CYP2C9*3: "],
    ["Cai, W.M., et al.",1999,"The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014184/","Propafenone","CYP2D6","pre/post","Cardiology","Dizziness, nausea, gastric irritation - 2~3 fold higher plasma propafenone concentration seen in poor metabolizers of CYP2D6 when compared to extensive metabolizers. Consequently, a lower clearance of propafenone was observed. Therefore, mutations of CYP2D6 affects the variability of propafeNone pharmacokinetics. ","CYP2D6 Poor Metabolizers"],
    ["Pirmohamed, M., et al.",2003,"Cytochrome P450 enzyme polymorphisms and adverse drug reactions","http://www.sciencedirect.com/science/article/pii/S0300483X03002476","Propafenone","CYP2D6","peri","Cardiology","Arrhytmia","CYP2D6*4:CYP2D6*5:CYP2D6*10:CYP2D6*17"],
    ["Lymperopoulos, A., et al.",2015,"Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.","https://www.ncbi.nlm.nih.gov/pubmed/26537419","Propanolol","CYP2D6","peri","Cardiology","Bradycardia, hypotension,decreased therapeutic effect. ","CYP2D6*1:  CYP2D6*2 : CYP2D6*3 : CYP2D6*4 : CYP2D6*5 : CYP2D6*6 :  CYP2D6*9 : CYP2D6*10 : CYP2D6*17 : CYP2D6*41 : CYP2D6*1XN : CYP2D6*2XN"],
    ["Wang, Y., et al.",2017,"Relationship between UGT1A9 gene polymorphisms, efficacy, and safety of propofol in induced abortions amongst Chinese population: a population-based study.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653915/","Propofol","UGT1A9 ","intra","Anesthesiology","Higher induction dose required.","1887 T/G"],
    ["Sowinkski, K.M., et al.",2012,"Impact of CYP2D6 Poor Metabolizer Phenotype on PropraNolol Pharmacokinetics and Response","https://onlinelibrary.wiley.com/doi/abs/10.1002/j.1875-9114.1997.tb03097.x","Propranolol","CYP2D6","pre/post","Cardiology","Increased plasma concentration due to poor metabolism - PropraNolol hydrochloride existed in three different crystalline forms, deNoted as forms I, II and III, according to their decreasing melting temperatures. CYP2D6","CYP2D6 Poor metabolizers"],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Protriptyline","CYP2D6","pre/post","Psychiatry","Increased plasma concentration - due to CYP2D6 poor metabolizer, lower doses of protriptyline are recommended ","CYP2D6 Poor metabolizers"],
    ["Hogan, D.B.",2015,"Quinine: Not a safe drug for treating Nocturnal leg cramps","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347765/","Quinine sulfate","G6PD","pre/post","Infectious Disease","arrhythmias and haemolysis - due to G6PD deficiency ","G6PD "],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Quinolones (Nalidixic acid, Ciprofloxacin, Ofloxacin)","G6PD deficiency","pre/post","Infectious Disease","acute hemolytic anemia due to G6PD deficiency","G6PD  "],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Rabeprazole","CYP2C19","pre/post","Gastroenterology","ventilator acquired pneumonia (poor metabolizers).","CYP2C19*2"],
    ["Miura, M., et al.",2007,"Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients","http://onlinelibrary.wiley.com/doi/10.1002/bdd.544/full","Rabeprazole","CYP2C19 : CYP3A5 : MDR1","pre/post","Gastroenterology","Patients with genetic polymorphisms need lower dosages of tacrolimus to achieve the target therapeutic index.","CYP3A5*3/*3"],
    ["Miura, M., et al.",2005,"Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers","http://www.tandfonline.com/doi/abs/10.1080/00498250500111562","Rabeprazole","CYP2C19","pre/post","Gastroenterology","Renal-transplant recipients who are CYP2C19 extensive metabolizers, there is less stereoselective difference in the pharmacokinetic disposition between the (R)- and (S)-enantiomers of rabeprazole than those of lansoprazole.","-"],
    ["Mahajan, P. ",2016,"Recent Advances in Application of Pharmacogenomics for Biotherapeutics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256619/","Rasburicase","CYB5R","post","Oncology","increased hemolysis.","CYB5R1-4"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Rasburicase","G6PD","post","Oncology","hemolytic anemia in patients with G6PD deficiency.","G6PD C563T "],
    ["Mahajan, P.B.",2016,"Recent Advances in Application of Pharmacogenomics for Biotherapeutics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256619/","Rasburicase","CYB5R:G6PD","pre/post","Oncology","Exhibit increased hemolysis- Due to reduced CYB5R1-4 activity and G6PD deficiency ","CYB5R*1,*2,*3,*4:G6PD deficiency"],
    ["Relling, M.V., et al.",2014,"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111801/","Rasburicase","G6PD","pre/post","Oncology","Acute hemolytic anemia and methemoglobinemia (apply to neonates , children, and adults) -It is concluded that rasburicase is contraindicated in patients with G6PD  deficiency.","G6PD "],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Rasburicase","G6PD deficiency","pre/post","Rheumatology","Acute hemolytic anemia due to G6PD deficiency","G6PD "],
    ["Zabriskie, M.S., et al.",2014,"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160372/","Rebastinib","BCR-ABL1","pre/post","Oncology","Relapse of disease- Mutations in BCR-ABL1 may confer resistance and treatment failure leading to disease progression. T315I mutants are also found to confer high-level resistance to Tyrosine Kinase Inhibitors.","BCR-ABL1:M244, G250, Q252, Y253, E255, V299, F311, T315, F317, M351, F359, and H396:T315I"],
    ["Nishimura, T., et al.",2012,"Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.","https://www.ncbi.nlm.nih.gov/pubmed/22052220","Ribavirin","ITPA ","pre/post","Infectious Disease","Ribavirin induced anemia - seen in Hepatitis C patients that use ribavirin and ITPA polymorphism","ITPA(CC) rs1127354 "],
    ["Ramappa, V., et al.",2013,"Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940184/","Rifampin","HLA-DQA1","pre","Infectious Disease","Drug induced hepatotoxicity","HLA-DQB1*0201"],
    ["Eum, S., et al.",2016,"Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067149/","Risperidone","CYP2D6","pre/post","Psychiatry"," Weight gain and hyperprolactinemia","CYP2D6 *9 :  CYP2D6 *10 :  CYP2D6*17 : CYP2D6*29 : CYP2D6*36 :  CYP2D6 *41 "],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Risperidone","CYP2D6","peri","Psychiatry","Increased sedation in poor metabolizers","CYP2D6*3: CYP2D6*4: CYP2D6*5: CYP2D6*6"],
    ["Puangpetch, A., et al.",2016,"CYP2D6 polymorphisms and their influence on risperidone treatment","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138038/","Risperidone","CYP2D6","pre/post","Psychiatry","Hyperprolactinemia, weight gain, extrapiramidal adverse reactions - CYP2D6 metabolizes risperidone to the active metabolite of 9-hydroxyrisperidone. Studies explain that risperidone may be more toxic than its active metabolite. Polymorphisms that lead to decreased CYP2D6 activity lead to increased risperidone concentrations. Some adverse effects are due to increased dopamine D2 receptor blockage in the anterior pituitary that lead to increased prolactin.  ","CYP2D6*3:CYP2D6*4:CYP2D6*5 (No enzymatic activity). CYP2D6*10:CYP2D6*41(reduced enzymatic activity):CYP2D6*1:CYP2D6*2:CYP2D6*33:CYP2D6*35 (Normal enzymatic activity)."],
    ["Asahina, Y., et al.",2013,"Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521272/","Rivavirin","IFNl3 gene (IL28B)","pre/post","Infectious Disease","Higher gamma-glutamyltranspeptidase levels, higher frequency of hepatic steatosis, lower low density lipoprotein cholesterol levels, No response or resistance to PEG-IFNa/RBV treatment.","IL28B rs12979860 CT and TT or IL28B rs8099917 TG and GG genotypes "],
    ["Birmingham, B.K., et al.",2015,"Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.","https://www.ncbi.nlm.nih.gov/pubmed/25630984","Rosuvastatin","SLCO1B1: COQ2","pre/post","Cardiology","Myopathy","SLCO1B1 T521>C "],
    ["Birmingham, B.K., et al.",2015,"Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.","https://www.ncbi.nlm.nih.gov/pubmed/25630984","Rosuvastatin","ABCG2","pre/post","Cardiology","Myopathy","ABCG2 C421>A  "],
    ["DeGorter, M.K., et al.",2013,"Clinical and Pharmacogenetic predictors of Circulating Atorvastatin and Rosuvastatin Concentration in Routine Clinical Care","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922121/","Rosuvastatin","SLCO1B1:ABCG2","pre/post","Endocrinology","Increase plasma concentarations, reduced LDL-C lowering response to rosuvastatin therapy - SLCO1B1 polymorphisms lead to reduced function in the uptake transporters and mutations in the efflux transporter ABCG2. ","SLCO1B1c.521T>C (rs4149056):ABCG2c.421C>A"],
    ["Dockery, L.E., et al.",2017,"Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488752/","Rucaparib","BRCA:RAD:NHEJ","pre/post","Oncology","Resistance to rucaparib- reversion mutations lead to the regained function of the proteins in the tumor cells and therefore resistance to treatment. ","BRCA1:RAD51C:RAD51D:NHEJ"],
    ["Drew, Y., et al.",2016,"Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882768/","Rucaparib","BRCA","pre/post","Oncology","Most patients had reduced clinical efficacy during intermitent dosing- continous dosing may be required to sustain PARP inhibition and obtain optimal response","BRCA1:BRCA2"],
    ["Turhan, K.S., et al.",2013,"Delayed Onset Malignant Hyperthermia after Sevoflurane","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683465/","Sevoflurane","RYR1","intra","Anesthesiology","Maliginant hyperthermia - ryanodine receptor mutation has shown to cause malignant hyperthermia after anesthesia with sevoflurane. Patients symptoms have shown to improove after discontinuation of sevoflurane. It is recommended to evaluate the patient for clinical signs of King-Denborough syndrome during the preoperative period. ","Gly4932Ser ,RYR1 CYP2E1"],
    ["Harrison-Woolrych, M., et al. ",2006,"QT interval prolongation associated with sibutramine treatment","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885035/","Sibutramine","KCNQ1","pre","Gastroenterology"," Torsades de Pointes due to QTc prolongation.","KCNQ T265I "],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Simvastatin","CYP2D6","pre/post","Cardiology","Higher LDL cholesterol levels due to decreased efficacy"," CYP3A5*1 c.6986A>G rs776746"],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Simvastatin","SLCO1B1","pre/post","Cardiology","Myopathy","SLCO1B1 c.521T>C"],
    ["Brunham, L.R., et al.",2012,"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.","https://www.ncbi.nlm.nih.gov/pubmed?term=Differential%20effect%20of%20the%20rs4149056%20variant%20in","Simvastatin","SLCO1B1","peri","Cardiology","Simvastatin-associated myopathy","SLCO1B1*5, SLCO1B1*15, SLCO1B1*17)"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Simvastatin","SLCO1B1","pre/post","Cardiology","Myopathy or fatal rhabdomyolysis","SLCO1B1 rs4363657 : SLCO1B1 rs4149056"],
    ["CostantiNo, A., et al.",2015,"Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650141/","Sofosbuvir","HCV NS5B polymerase","pre/post","Infectious Disease","poor response to sofosfuvir treatment in genotype 1b HCV chronically infected patients. ","C316N/H in NS5B region"],
    ["Meissner, E.G., et al.",2013,"IFNL4-?G Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017364/","Sofosbuvir","IFNL4-?G","pre/post","Infectious Disease","decreased drug efficacy and slower early viral decline for HCV genotype1- infected patients - if Sofosfuvir is given along with ribavirin and IFNL4-?G variant. This is due to ecreased drug efficacy and slower loss of the free virus. ","IFNL4-?G variant unfavorable heterozygous TT/?G rs368234815 genotype: heterozygous CT rs12979860 genotype: homozygous ?G/?G rs368234815 genotype"],
    ["Dean, L. ",2017,"Sofosbuvir Therapy and IFNL4 Genotype","https://www.ncbi.nlm.nih.gov/books/NBK409960/","Sofosbuvir","IFNL3 (IL28B)","peri","Infectious Disease","Homozygosity for the rs12979860-C allele (IL28B-CC genotype) assoc. w/faster viral kinetic (VK) decline and higher odds of achieving SVR with IFN-?/RBV therapy. The genetic variant rs12979860, located in the INFL4 gene, is a strong predictor of response to peginterferon-based therapies. The variant is a C to T change—individuals with the favorable “C/C” genotype have about a 2-fold higher likelihood of achieving SVR compared to individuals with CT or TT genotypes","The rs12979860 allele is located in the INFL4 gene. The variant is a C to T change. Individuals can have  IL28B-CC, IL28B-CT or IL28B-TT genotypes"],
    ["El Rouby, N., et al.",2015,"Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717470/","Spironolactone","CYP4A11","pre/post","Cardiology","Increased risk of volume-dependent renal hypertension as a consequence of sodium and water retention - due to reduced activity of CYP4A11","CYP4A11 rs3890011"],
    ["Hicks, J.K., et al.",2015,"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908/","SSRIs","CYP2D6 : CYP2C19","pre","Psychiatry"," Vomiting, diarrhea, hypertension, tachycardia, and prolonged QTc interval","CYP2D6*1:  CYP2D6*2 : CYP2D6*3 : CYP2D6*4 : CYP2D6*5 : CYP2D6*6 :  CYP2D6*9 : CYP2D6*10 : CYP2D6*17 : CYP2D6*41 : CYP2D6*1XN : CYP2D6*2XN : CYP2C19*1 : CYP2C19*2 : CYP2C19*3 : CYP2C19*17 "],
    ["SEARCH Collaborative Group.",2008,"SLCO1B1 variants and statin-induced myopathy--a geNomewide study.","https://www.ncbi.nlm.nih.gov/pubmed/18650507","Statin therapy","SLCO1B1","peri","Cardiology","Increased risk of statin-induced myopathy","SLCO1B1*5"],
    ["Arrigoni, E., et al. ",2017,"Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297738/","Statins","ABCB1","pre/post","Cardiology","Myalgia, increase in total  and HDL cholesterol levels","ABCB1c.3435C>T."],
    ["Oh, J., et al.",2007,"Genetic determinants of statin intolerance","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1832194/","Statins","COQ2","pre/post","Cardiology","Myopathy","COQ2 rs6535454: COQ2 rs4693075"],
    ["Gerr, F., et al.",1994,"Hemolytic Anemia Following Succimer Administration in a Glucose-6-Phosphate Dehydrogenase Deficient Patient","https://www.tandfonline.com/doi/abs/10.3109/15563659409011061?journalCode=ictx19","Succimer","G6PD","pre/post","Hematology","hemolytic anemia","G6PD"],
    ["Alvarellos, M.L., et al.",2015,"PharmGKB Summary: Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631707/","Succinylcholine","BCHE","intra","Anesthesiology","Increased duration prolonged apnea in presence of succinylcholine - the increased duration depends on the type and amount of variants existing","BCHE (rs28933389:rs28933390:rs1799807:rs121918558:rs104893684:rs121918557:rs121918556:rs1803274)"],
    ["Alvarellos, M.L., et al.",2015,"PharmGKB Summary: Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631707/","Succinylcholine","CACNA1S","intra","Anesthesiology","Malignant hyperthermia - Possibly due to elevated basal calcium in skeletal muscle. In polymorphisms such as NP_000060.2: p.Arg1086His; rs1800559 C>T, an arginine residue is substituted by histidine. In polymorphisms such as NP_000060.2: Arg174Trp c.520 C>T; rs772226819, and arginine residue is substituted by tryptophan.","CACNA1S (rs772226819: rs1800559)"],
    ["Alvarellos, M.L., et al.",2017,"PharmGKB Summary: Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631707/","Succynilcholine","RYR1 : CACNA1S","intra","Anesthesiology","Malignant hyperthermia"," Chromosome 3q13.1 RYR1 : Chromosome 7q21.11 CACNA2D1"],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Sulfadiazine","G6PD deficiency","pre/post","Infectious Disease","acute hemolytic anemia due to G6PD deficiency","G6PD  "],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Sulfamethoxazole","HLA-B","pre/post","Infectious Disease","Steven Johnson Syndrome, toxic epidermal necrolysis","HLA-B*3802 "],
    ["Wang, D., et al.",2012,"Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418550/","Sulfamethoxazole (SMX)","GCLC","pre","Infectious Disease","SMX-induced hypersensitivity in HIV/AIDS patients- the miNor G allele of the polymorphism rs761142 showed reduced GCLC mRNA expression in both B-lymphocytes and livers. ","rs761142 "],
    ["Tanaka, E., et al.",2002,"Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene","http://www.jrheum.org/content/29/12/2492.short","Sulfasalazine","NAT","pre/post","Gastroenterology","The slow acetylators who had No NAT2*4 haplotype had experienced adverse effects more frequently (62.5%) than the fast acetylators who had at least one NAT2*4 haplotype","NAT*4"],
    ["Richardson, S.R.",2017,"Glucose 6 Phosphate Dehydrogenase (G6PD) Deficiency.","https://www.ncbi.nlm.nih.gov/pubmed/29262208","Sulfisoxazole","G6PD","pre/post","Infectious Disease","Risk of hemolytic anemia for G6PD deficient individuals ","G6PD"],
    ["Delacour, H., et al. ",2014,"Characterization of a Novel BCHE “Silent” Allele: Point Mutation (p.Val204Asp) Causes Loss of Activity and Prolonged Apnea with Suxamethonium","https://www.ncbi.nlm.nih.gov/pubmed/25054547","Suxamethonium","BCHE","intra","Anesthesiology","Prolonged neuromuscular blockade and apnoea due to increasing the drug duration of action.","BCHE  p.Val204Asp"],
    ["Simon, T., et al.",2000,"Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity","https://www.ncbi.nlm.nih.gov/pubmed/10801254","Tacrine","GST ","pre","Neurology ","Increases tacrine hepatotoxicity.","GST-T1 (?/?) null genotype"],
    ["Okada, R., et al.",2010,"Direct and Rapid Genotyping of Glutathione-S-transferase M1 and T1 from Human Blood Specimens Using the SmartAmp2 Method","http://dmd.aspetjournals.org/content/38/10/1636#F1","Tacrine","GST M1","pre","Neurology ","Elevation in serum transaminases","GST-M1 (?/?) null genotype"],
    ["Miura, M., et al.",2007,"Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients","http://onlinelibrary.wiley.com/doi/10.1002/bdd.544/full","Tacrolimus","CYP2C19 : CYP3A5 : MDR1","pre/post","Gastroenterology","Patients with genetic polymorphisms need lower dosages of tacrolimus to achieve the target therapeutic index.","CYP3A5*3/*3"],
    ["StefaNovic, N., et al",2015,"Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533232/","Tacrolimus","CYP3A5 : ABCB1","pre/post","Oncology ","nephrotoxocity, chronic allograft nephropathy ","ABCB1 3435C>T :  CYP3A5*1/*1 :  CYP3A5*1/*3 :  CYP 3A5*3/*3"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Tacrolimus","CYP3A4","post","Oncology ","Reduced metabolism leading to enhanced immune effect instead of immune supression (poor metabolizer)","CYP3A4*3"],
    ["O’Sullivan Coyne, G., et al.",2017,"PARP Inhibitors in Reproductive System Cancers: Current Use and Developments","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266774/","Talazoparib","SLFN11","pre/post","Oncology","Resistance to talazoparib- SLFN11 inactivation can predispose to a mechanism of PARPi resistance. It is suggested that talazoparib therapy resistance can be overcome when combined with ATR inhibitors VE-821.","SLFN11"],
    ["Brauch, H., et al.",2014,"Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971985/","Tamoxifen","CYP2D6","pre/post","Gynecology ","Less tamoxifen benefit and higher odds of disease event in poor metabolizers CYP2D6*4,*6 - Endoxifen concentrations are foud to be higher in ultrarapid and extensive metabilizers and lowest in poor metabolizers. Therefore, tamoxifen benefits of Extensive metabolizers over poor metabolizers. ","CYP2D6*3,*4,*5,*6 (poor metabolizers): CYP2D6*10,*17,*41(intermediate metabolizers): CYP2D6*1xN,*2xN(ultra-rapid metabolizers)"],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Tamoxifen","CYP2D6","pre/post","Oncology","Increased estrogen receptor-positive breast cancer reccurence (Neary twofold higher incidence)- Caused by reduced or loss of function of CYP2D6.","CYP2D6*3:CYP2D6*4:CYP2D6*5"],
    ["Li, J., et. al.",2013,"Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment","https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3495","Tamoxifen","CYP2D6","pre/post","Oncology"," Mammographic density change in patients with breast cancer","CYP2D6*10 : CYP2D6*41:  CYP2D6*3 : CYP2D6*4 : CYP2D6*5"],
    ["Rodriguez-Antona, C.,et al.",2015,"PharmacogeNomic biomarkers for personalized cancer treatment ","http://onlinelibrary.wiley.com/doi/10.1111/joim.12321/full","Tamoxifen","F5","pre/post","Oncology ","Patients who were Factor V Leiden carriers had increased toxicity with tamoxifen than patients without this mutation. ","F5 Factor V Leiden carriers"],
    ["Rodriguez-Antona, C.,et al.",2015,"PharmacogeNomic biomarkers for personalized cancer treatment ","http://onlinelibrary.wiley.com/doi/10.1111/joim.12321/full","Tamoxifen","F2","pre/post","Oncology ","Patients with the prothrombin mutation G20210A were more likely to have toxicity with tamoxifen. ","F2 G20210A"],
    ["Yan, J., et al. ",2008,"Estrogen Receptor Genotypes Influence Hot Flash prevalence and Composite Score Before and After Tamoxifen Therapy ","http://ascopubs.org/doi/abs/10.1200/jco.2008.16.8377","Tamoxifen","ESR","pre/post","Oncology ","In premenopausal women, increased number of the ESR1 PvuII and XbaI CG alleles were associated with increased numbers of hot flashes. Women who had the ESR2-02 AA genotype were less likely to experience tamoxifen induced hot flashes. ","ESR-02AA"],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Tegafur","CYP2A6 : DPYD","pre/post","Oncology","Neurotoxicity, diarrhea, and myelosuppresion. ","CYP2A6*1A : CYP2A6*4A  del :  CYP2A6*4A-H del : CYP2A6*7 : CYP2A6*9 : DPYD c.1905+1G>A : DPYD c.1679T>G : DPYD c.2846A>T  : DPYD c.2579delA  : DPYD c.1129-5923C>G "],
    ["Muir, A., et al. ",2013,"Clinical Phamacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and Peg Interferon-alpha-Based Regiments ","http://onlinelibrary.wiley.com/doi/10.1038/clpt.2013.203/full","Telaprevir","IFNL3","pre/post","Infectious Disease","IFNL3 genotype is the strongest predictor of treatment response to PEG-IFN-alpha and RBV therapy in patients with hepatitis C infection. ","IFNL3 rs12979860 rs8099917"],
    ["Mehanna, R., et. al. ",2012,"Analysis of CYP2D6 genotype and response to tetrabenazine ","http://onlinelibrary.wiley.com/doi/10.1002/mds.25278/full","Tetrabenazine","CYP2D6","pre/post","Neurology ","Ultra-rapid metabolizers required a longer titration to recieve optimal benefits of the medication and requires a higher average daily dose when compared to other patients. ","CYP2D6 ultrarapid metabolizers "],
    ["Lennard, L., et al. ",1987,"Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucloetide concentrations ","http://onlinelibrary.wiley.com/doi/10.1038/clpt.1987.4/full","Thioguanine","TPMT","pre/post","Oncology ","Low TPMT activity is a risk factor for elevated 6-TGN concentrations and the development of severe leukopenia in patients on thiopurine drugs ","low TPMT activity "],
    ["Rodriguez-Antona, C.,et al.",2014,"PharmacogeNomic biomarkers for personalized cancer treatment","https://onlinelibrary.wiley.com/doi/full/10.1111/joim.12321","Thiopurine","TPMT","pre/post","Oncology","Neutropenia and toxicity - due to polymorphisms in TPMT","TPMT polymorphisms"],
    ["Higgs, J.E., et al.",2010,"Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?","https://www.ncbi.nlm.nih.gov/pubmed/20136357","Thiopurine drugs","TPMT","pre/post","Oncology","Increased risk of myelosuppression ","TPMT *2: TPMT *3A: TPMT *3B: TPMT *3C: TPMT *4"],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Thioridazine","CYP2D6","pre/post","Psychiatry","Risk for ventricular arrhytmia - due to loss-of-function of CYP2D6 genotype","CYP2D6 loss-of-function"],
    ["Eum, S., et al.",2016,"Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067149/","Thioridazine","CYP2D6","pre/post","Psychiatry","QTc interval prolongation","CYP2D6 *9 :  CYP2D6 *10 :  CYP2D6*17 : CYP2D6*29 : CYP2D6*36 :  CYP2D6 *41 "],
    ["Bertholee,  D., et al. ",2017,"Genotypes Affecting the Pharmacokinetics of Anticancer Drugs","https://link.springer.com/article/10.1007/s40262-016-0450-z#Sec12","Thiotepa","GSTP1 ","pre/post","Oncology","Hematological toxicity, mucositis ,myelodysplastic syndromes and acute Non-lymphocytic leukemia ","GSTP1 (c.341C>T) rs1138272"],
    ["Beitelshees, A.L., et al.",2015,"Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397717/","Ticagrelor","SLC01B1","post","Cardiology"," SLC01B1*5 loss of function variant were associated with higher ticagrelor and active metabolite levels. ","SLC01B1*5"],
    ["Evans, W.E., et al.",2003,"Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects","http://www.nejm.org/doi/10.1056/NEJMra020526","TMP/SMX","KCNE2","pre/post","Cardiology","KCNE2 variants have been associated with the development of a very long QT interval after therapy with trimethoprim–sulfamethoxazole, with sulfamethoxazole inhibiting potassium channels encoded by the KCNE2 (8T?A) variant","KCNE2 (8T-A)"],
    ["Hansen, T., et al.",1998,"Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene","http://diabetes.diabetesjournals.org/content/47/4/598.full-text.pdf","Tolbutamine","SUR1","pre/post ","Endocrinology","Decreased insulin response","Asp673Asn:Ser1369Ala:Thr759Thr"],
    ["Ingelman-Sundberg, M. ",2005,"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity ","https://www.ncbi.nlm.nih.gov/pubmed/20530222","Tolterodine","CYP2D6","pre/post","Urology","Different mutations of the CYP2D6 gene affect the rate of metabolism of tolterodine. ","CYP2D6*10"],
    ["Luzzatto, L., et al.",2014,"G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153881/","Toluidine blue","G6PD deficiency","pre/post","Oncology","Acute hemolytic anemia due to G6PD deficiency","G6PD "],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Tramadol","CYP2D6","post","Anesthesiology","Decreased plasma levels of O-desmethyltramado and reduced analgesic effects in patients woth polymorphic poor metabolizer CYP2D6.",""],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Tramadone","CYP2D6","peri","Neurology","Increased analgesic effect in poor metabolizer","CYP2D6*3: CYP2D6*4: CYP2D6*5: CYP2D6*6"],
    ["Pratt, V., et al. ",2017,"Dabrafenib Therapy and BRAF and G6PD Genotype.","https://www.ncbi.nlm.nih.gov/pubmed/28809523","Trametinib","BRAF","pre/post","Oncology ","Dabrafenib can be used as a single agent to treat melanoma with the BRAF V600E variant, or in combination with the MEK inhibitor trametinib to treat melanoma with BRAF V600E or V600K variants.","BRAF 600E/ 600K "],
    ["Pratt, V., et al. ",2017,"Dabrafenib Therapy and BRAF and G6PD Genotype.","https://www.ncbi.nlm.nih.gov/pubmed/28809523","Trametinib","G6PD","pre/post","Oncology ","Patients with G6PD deficiency can have hemolytic anemia while uisng dabrafenib","G6PD deficiency "],
    ["Robert, C., et al. ",2015,"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","http://www.nejm.org/doi/full/10.1056/nejmoa1412690#t=article","Trametinib","RAS","pre/post","Oncology ","The combination of dabrafenib with trametinib was superior to vemurafenib monotherapy in melanoma patients with BRAF V600E or C600K mutations ","BRAF V600E or V600K"],
    ["Katoh, M., et al.",2007,"Glucuronidation of Antiallergic Drug, Tranilast: Identification of Human UDP-Glucuronosyltransferase Isoforms and Effect of Its Phase I Metabolite","http://dmd.aspetjournals.org/content/35/4/583.long","Tranilast","UGT1A1","post","Pulmonary","Unconjugated hyper-bilirubinaemia in Gilbert's syndrome","UGT1A1*28"],
    ["CoNolly, R., et al.",2009,"The role of pharmacogenetics in selection of breast cancer treatment ","https://www.ncbi.nlm.nih.gov/books/NBK247013/","Trastuzumab","CYP2D6","pre/post","Oncology ","Genetic polymorphisms in the CYP2D6 gene and pharmacologic inhibition of the enzyme have been associated with altered tamoxifen metabolism, adverse event profile, and clinical benefit.","CYP2D6 intermediate and poor metabolizers"],
    ["Piccart-Gebhard, et. al. ",2005,"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","http://www.nejm.org/doi/full/10.1056/NEJMoa052306#t=article","Trastuzumab","HER2","pre/post","Oncology ","Trastuzumab was beneficial in woman with HER-2 positive breast cancer after completion of adjuvant chemotherapy ","HER2-positive"],
    ["Warrell, R., et al. ",1991,"Differentiation Therapy of Acute Promyelocytic Leukemia with TretiNoin (All-trans-RetiNoic Acid)","http://www.nejm.org/doi/full/10.1056/NEJM199105163242002#t=article","Tretinoin","PML-RAR-alpha","pre/post","Oncology ","All patients who responded to treatment with tretinoin who were tested by Northern blot analysis had expression of aberrant RAR-?.","RAR-alpha q22;ql2–21"],
    ["Hicks, et al. ",2013,"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants","https://www.ncbi.nlm.nih.gov/pubmed/14520122","Trimipramine","CYP2C19","pre/post","Psychiatry","Polymorphisms in CYP2C19 affect the efficacy and safety of tricyclics,","CYP2C19*3/*3"],
    ["Della-Morte, D., et al.",2014,"Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.","https://www.ncbi.nlm.nih.gov/pubmed/25521362","Troglitazone","GSTT1:GSTM1:CYP2C19:CYP2D6:Pro12Ala","pre/post","Endocrinology","Abnormal increase in ALT levels - due to the combined null polymorphism of GSTT1*600436 and GSTM1*138350. Troglitazone induced liver injury - in patients with CYP2C19*1,*2,*3:CYP2D6*1,*2,*5,*10 polymorphisms. Weight gain - in Pro12Ala polymorphism. ","GSTT1*600436:GSTM1*138350:CYP2C19*1,*2,*3:CYP2D6*1,*2,*5,*10:Pro12Ala"],
    ["Okada, R., et al.",2010,"Direct and Rapid Genotyping of Glutathione-S-transferase M1 and T1 from Human Blood Specimens Using the SmartAmp2 Method","http://dmd.aspetjournals.org/content/38/10/1636#F1","Troglitazone","GSTT1","pre","Endocrinology","Elevation in serum transaminases","GST-T1 (?/?) null genotype"],
    ["Okada, R., et al.",2010,"Direct and Rapid Genotyping of Glutathione-S-transferase M1 and T1 from Human Blood Specimens Using the SmartAmp2 Method","http://dmd.aspetjournals.org/content/38/10/1636#F1","Troglitazone","GSTM1","pre","Endocrinology","Elevation in serum transaminases","GST-M1 (?/?) null genotype"],
    ["Basile, V. et. al",2000,"A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia ","https://search.proquest.com/openview/77eaa116d64b4ab45315389d723fda64/1?pq-origsite=gscholar&cbl=44096","Typical antipsychotics","CYP1A2","pre/post","Psychiatry","Polymorphism in CYP1A2 may serve as a risk factor for the development of tardive dyskinesia in patients with schizophrenia taking typical antipsychotics ","CYP1A2 C/C genotype"],
    ["Basile, V. et. al",2000,"A functional polymorphism of the cytochrome P450 1A2 (CYP1A1) gene: association with tardive dyskinesia in schizophrenia","http://www.nature.com/mp/journal/v5/n4/full/4000736a.html?foxtrotcallback=true","Typical Antipsychotics: Chlorpromazine","CYP1A2:CYP2D6","preintra","Psychiatry","Tardive dyskinesia","Bsp120I"],
    ["Alvarellos, M.L., et al.",2015,"PharmGKB Summary: Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631707/","Uccinylcholine","RYR1","intra","Anesthesiology","Malignant hyperthermia - elevated basal calcium in skeletal muscle","RYR1 (rs193922747:rs118192161:rs193922753: rs1801086: rs121918592: rs118192116: rs118192162: Rs111888148:  rs193922770: rs193922772: rs118192172: rs118192175: rs118192163: rs118192176: rs118192177: rs118192177: rs112563513: rs193922802: rs193922807: rs193922809: rs121918593: rs28933396: rs193922816: rs118192122: rs28933397:  rs121918594: rs118192178: rs118192167: rs121918595: rs193922876: rs193922878: rs63749869: rs118192170)"],
    ["Galluzzo, M., et al. ",2016,"IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response prediction in Psoriasis","https://www.karger.com/Article/Abstract/441719","Ustekinumab","IL12A:IL12B:IL23A","pre/post","Dermatology ","The presence of the GG genotype on the IL12B rs6887695 SNP and absence of the AA genotype on the IL12B rs3212227 SNP significantly increase the probability of therapeutic success in HLA-Cw6 positive patients.","CG genotype on IL12B rs6887695 SNP"],
    ["Cornett, E., et al. ",2017,"Medication-Induced Tardive Dyskinesia: A Review and Update","http://www.ochsnerjournal.org/doi/abs/10.1043/TOJ-16-0108?code=occl-site","Valbenazine","CYP2D6","pre/post","Neurology ","This review highlights the need for a prevention-based focus of TD treatment that starts with a clinical consideration of pharmacologic choices related to each individual patient's history.","CYP2D6 slow, intermediate and ultrarapid metabolizers"],
    ["Lheureux, P., et al. ",2009,"Carnitine in the treatment of vaploric-acid induced toxicity ","http://www.tandfonline.com/doi/abs/10.1080/15563650902752376","Valproic Acid","Urea cycle disorders","pre/post","Neurology ","Urea cycle disorders increase the risk of valproic acid toxicity. ",""],
    ["Su, F., et al. ",2012,"RAS mutations in cutaneous squamous-cell carincomas in patients treated with BRAF inhibitors ","http://www.nejm.org/doi/full/10.1056/NEJMoa1105358#t=article","Vemurafebin","RAS","pre/post","Oncology ","The anti-tumor activit of vemurafenib is against BRAF V600E mutant cells","BRAF V600E "],
    ["Jang, S., et al.",2013,"Which drug, and when, for patients with BRAF-mutant melanoma?","http://www.sciencedirect.com/science/article/pii/S1470204512705399","vemurafenib","BRAF, mainly at codon 600, which result in constitutive activation of the MAPK pathway","pre/post","Oncology","growth of cutaneous squamous-cell carcinomas","BRAF, mainly at codon 600, which result in constitutive activation of the MAPK pathway"],
    ["William, L. ",2016,"Venetoclax Shows Efficacy In Refractory 17p[del] CLL","http://oncologypro.esmo.org/Oncology-News/Daily-News/Venetoclax-Shows-Efficacy-In-Refractory-17p-del-CLL","Venetoclax","Chromosome 17p","pre/post","Oncology ","Patients with hard to treat CLL with a 17p deletion benefit from BCL2 inhibitor venetoclax treatment ","Chromosome 17p deletion"],
    ["Lessard, E., et al. ",1999,"Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans ","http://journals.lww.com/jpharmacogenetics/abstract/1999/08000/influence_of_cyp2d6_activity_on_the_disposition.2.aspx","Venlafaxine","CYP2D6","pre/post","Psychiatry","Poor metabolizers have decreased venlafaxine clearance and this mutation may also be associated with cardiovascular toxicity. ","CYP2D6 poor metabolizers "],
    ["Vinetti, M., et al.",2011,"Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.","https://www.ncbi.nlm.nih.gov/pubmed/22077251","Venlafaxine","CYP2D6","pre/post","Psychiatry","Cardiotoxixity- due to prolonged or absent metabolism of Venlafaxine and therefore an increase in the medication concentration caused by CYP2C19 and CYP2D6 polymorphisms.","CYP2D6*5"],
    ["Rocha, J.C.C, et al.",2017,"Pharmacogenetics of outcome in children with acute lymphoblastic leukemia","http://www.bloodjournal.org/content/105/12/4752.long?sso-checked=true","Vincristine","TYMS","post","Oncology","Drug resistance, hematological relapse ","TYMS 3/3"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Voriconazole","CYP2C19","peri","Infectious Disease","therapeutic failure with Voriconazole in Ultra metabolizers","CYP2C19*2"],
    ["Gopisankar, M. ",2017,"CYP2D6 pharmacogenomics ","http://www.sciencedirect.com/science/article/pii/S1110863017300228","Vortioxetine","CYP2D6","pre/post","Psychiatry","Mutations in CYP2D6 can alter the metabolism of vortioxetine which may increase the risk of side effects in poor metabolizers. ","CYP2D6 poor metabolizers "],
    ["Dean, L.",2016,"Warfarin Therapy and the Genotypes CYP2C9 and VKORC1","https://www.ncbi.nlm.nih.gov/books/NBK84174/","Warfarin","CYP2C9","pre/post","Cardiology/Hematology","Increased bleeding risk","CYP2C9*2 :  CYP2C9*3 "],
    ["Dean, L.",2016,"Warfarin Therapy and the Genotypes CYP2C9 and VKORC1","https://www.ncbi.nlm.nih.gov/books/NBK84174/","Warfarin","VKORC1","pre/post","Cardiology/Hematology","Increased bleeding risk","VKORC1-1639G>A"],
    ["Krasowski, M. ",2015,"Current Diagnosis & Treatment : Family Medicine Chapter 49: Pharmacogenomics","http://accessmedicine.mhmedical.com/content.aspx?bookid=1415&sectionid=77060357","Warfarin","CYP2C9 ","pre/post","Cardiology/Hematology","Increased risk of bleeding at standard doses","CYP2C9?2 : CYP2C9?3"],
    ["Loebstein, R., et al.",2007,"A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.","http://www.bloodjournal.org/content/109/6/2477.long?sso-checked=true","Warfarin","VKORC1","pre/post","Cardiology/Hematology","Increased resistance to anticoagulation ","VKORC1 Asp36Tyr"],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Warfarin","CYP2C9 : VKORC1","pre/post","Cardiology/Hematology","Higher risk of thrombus formation, increased risk of severe bleeding","CYP2C9*1:  CYP2C9*2 :  CYP2C9*3 : VKORC1  G?A ?1639 "],
    ["Wei, C., et al.",2012,"Pharmacogenomics of adverse drug reactions: implementing personalized medicine","https://academic.oup.com/hmg/article/21/R1/R58/657865/Pharmacogenomics-of-adverse-drug-reactions","Warfarin","VKORC1","pre/post","Cardiology/Hematology","Higher risk of thrombus formation","VKORC1 G?A ?1639"],
    ["Cavallari, L.H., et al.",2011,"Role of cytochrome P450 genotype in the steps toward personalized drug therapy","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513224/","Warfarin","CYP2C9","post","Cardiology/Hematology","Increased risk of thrombosis and bleeding with subtherapeutic anticoagulation - The CYP2C9 genotype variability and reduced function allele leads to a decrease warfarin clearance. ","CYP2C9*3:CYP2C9*2:CYP2C9*5:CYP2C9*6:CYP2C9*8:CYP2C9*11"],
    ["D'Andrea, G., et al.",2005,"A polymorphism in the VKORCI gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin","https://www.researchgate.net/publication/8354856_A_polymorphism_in_the_VKORCI_gene_is_associated_with_an_interindividual_variability_in_the_dose-anticoagulant_effect_of_warfarin","Warfarin","VKORC1:CYP2C9 ","post","Cardiology/Hematology","To prevent bleeding, the mean adjusted dose of Warfarin should be adjusted depending on the present polymorphism. Mean adjusted dose of Warfarin was found to be lower when the following polymorphic genes present: 1173TT, 3730GG, CYP2C9*2, and CYP2C9*3, when compared to the following polymorphisms which need a higher dose of warfarin: 1173CT, 1173CC, and CYP2C9*1.","VKORC1*1173CC>T(rs9934438):VKORC1*3730G>A(rs7294):CYP2C9*2:CYP2C9*3"],
    ["Guruprasad, P.A., et al.",1999,"Association of of polymorphisms in the cytochrome P450 CYP269 with warfarin dose requirement and risk of bleeding complications","https://www.ncbi.nlm.nih.gov/pubmed/10073515","Warfarin","CYP2C9","pre/post ","Cardiology/Hematology","Hemorhage in patients with CYP2C9 allelic variant inducing lower than average warfarin dose requirement","CYP2C9*1:CYP2C9*2:CYP2C9*3"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Warfarin","CYP2C9","pre/post","Cardiology/Hematology","Patients with one or more variant CYP2C9 alleles (CYP2C9*2, CYP2C9*3) are at increased risk of excessive anticoagulation (INR exceeding 3) and bleeding. They require lower dosages of warfarin, particularly during initiation of therapy.","CYP2C9*2:CYP2C9*3"],
    ["Rieder, M.J., et al.",2005,"Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose","http://www.nejm.org/doi/full/10.1056/NEJMoa044503#t=articleDiscussion","Warfarin","VKORC1","post","Cardiology/Hematology","VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries. "," VKORC1 rs9923231 (3673G?A)"],
    ["Reiner, A., et al. ",2010,"PROC, PROCR, and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study","https://search.proquest.com/openview/49ff31618ed85f64ae23ae1addba8e6f/1?pq-origsite=gscholar&cbl=27990","Warfarin","PROS1","pre/post","Cardiology/Hematology","Mutations in PROS1 were associated with slightly lower protein S levels ","PROS1 rs4857343"],
    ["Reiner, A., et al. ",2010,"PROC, PROCR, and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study","https://search.proquest.com/openview/49ff31618ed85f64ae23ae1addba8e6f/1?pq-origsite=gscholar&cbl=27990","Warfarin","PROC","pre/post","Cardiology/Hematology","Mutations in PROC were associated with lower protein C levels","PROC rs2069901 "],
    ["Asensi, V., et al.",2015,"Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=nevirapine+side+effect+pharmacogenetic","Zidovudine","MTHFR:TS","pre/post","Infectious Disease","Increased risk of peripheral neuropathy and lipodystrophy in Spanish populations - due to Stavudine intake in patient with decreases TS expression and MTHFR polymorphism","TS:MTHFR1298(sn1801131)"],
    ["Haroldsen, P., et al.",2014,"Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate","https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.99","Amifampridine","NAT2","pre/post","Neurology","Adverse reactions such as seizures and hypersensitivity was seen in people with genetic variants in N-acetyltransferase gene 2 (NAT2) (poor metabolizers/ slow acetylators  )",""],
    ["Cruz, M. P., et al.  ",2016,"Aripiprazole Lauroxil (Aristada): An Extended-Release, Long-Acting Injection For the Treatment of Schizophrenia.","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010264/","ARIPiprazole Lauroxil","CYP2D6","pre/post","Psychiatry","To avoid adverse reaction, dosage adjustments are required when aripiprazole lauroxil is administered to CYP2D6 poor metabolizers. Adverse side effects include: cerebrovascular adverse reactions, including stroke, in elderly patients with dementia-related psychosis; neuroleptic malignant syndrome; tardive dyskinesia; metabolic abnormalities, such as hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain; orthostatic hypotension; leukopenia, neutropenia, and agranulocytosis; seizures; potential for cognitive and motor impairment; disruption of body temperature regulation; and dysphagia. ","CYP2D6*9,*10, and *41, CYP2D6*3?*6"],
    ["Danese, E.",2012,"Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731755/","Coumarin","CYP4F2 ","post","Hematology ","CYP4F2 p.V433M polymorphism affects daily maintenance coumarin dose, is highly significantly associated with increased daily dosage of coumarin anticoagulant.","CYP4F2 p.V433M"],
    ["Jacobson, I.M., et al. ",2016,"Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks","http://www.natap.org/2015/AASLD/AASLD_47.htm","Elbasvir","NS5A","pre/post","Infectious Disease","Lower the efficacy of the drug. ","NS5A*30:NS5A*31:NS5A*93 "],
    ["Pascual, T.",2017,"Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0180192","Everolimus","ABCB1 ","pre/post","Oncology","Mucositis","ABCB1 rs1045642"],
    ["Pascual, T.",2017,"Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0180192","Everolimus","PIK3R1 ","pre/post","Oncology","Hyperglycemia","PIK3R1 rs10515074"],
    ["Pascual, T.",2017,"Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0180192","Everolimus","RAPTOR ","pre/post","Oncology","Non-infectious pneumonitis","RAPTORrs9906827"],
    ["Pascual, T.",2017,"Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer","http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0180192","Everolimus","CYP3A4 ","pre/post","Oncology","Causes higher everolimus blood concentration","CYP3A4 rs35599367"],
    ["Dezentjé, V.O., et al.",2014,"CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM)trial.","https://link.springer.com/article/10.1007/s10549-013-2777-6","Exemestane","ESR : PGR (Hormone Receptor)","pre","Oncology","Hot flashes","-"],
    ["MacKenzie, M., et al.",2016,"Pharmacogenomics and pharmacogenetics for the intensive careunit: a narrative review","https://www.ncbi.nlm.nih.gov/pubmed/27752976","Fentanyl","CYP3A4","peri","Anesthesiology","Reduced metabolism leading to increased analgesic effect in poor metabolizer","CYP3A4*3"],
    ["Zhang, W., et al. ",2011,"Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery.","https://www.ncbi.nlm.nih.gov/pubmed/21513075","Fentanyl","CYP3A5:CYP3A4","post","Anesthesiology","Variation of post-operative fentanyl analgesic effect","CYP3A5*3 : CYP3A4*1G"],
    ["Hicks, J.K., et al.",2015,"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors.","http://onlinelibrary.wiley.com/doi/10.1002/cpt.147/full","Fluvoxamine","CYP2D6","pre/post","Psychiatry","Approximately 7% of the Normal population has a genetic code that leads to reduced levels of activity of CYP2D6 enzyme. Such individuals have been referred to as “poor metabolizers” (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While None of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 “extensive metabolizers” (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6. Caution is indicated in patient kNown to have reduced levels of cytochrome P450 2D6 activity and those receiving concomitant drugs kNown to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).","Carriers of poor metabolizer genotype"],
    ["Jacobson, I.M., et al. ",2016,"Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks","http://www.natap.org/2015/AASLD/AASLD_47.htm","Grazoprevir","NS5A","pre/post","Infectious Disease","Lower the efficacy of the drug. ","NS5A*30:NS5A*31:NS5A*94"],
    ["Campa, D. ",2007,"Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms with Morphine Pain Relief ","http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100385/full","Morphine","ABCB1:OPRM1","peri","Anesthesiology","Variation of pain relief in patients with corresponding genes' polymorphism  ","ABCB1/MDR1: SNPC3435TOPRM1: A80G SNP"],
    ["Bins, S.,",2016,"Association between single nucleotide polymorphisms and side effects in nivolumab treated NSCLC patients","https://academic.oup.com/anNonc/article-abstract/27/suppl_8/mdw525/2449686/1OAssociation-between-single-nucleotide?redirectedFrom=fulltext","Nivolumab","PTPN11","pre/post","Oncology","Higher odds of grade >3 toxicity and elevated liver enzymes","PTPN11 333-223A>G "],
    ["Dalén, P., et al. ",2000,"Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014903/","Quinidine","CYP2D6","pre/post","Cardiology","Treatment resistance - CYP2D6 ultrarapid metabolic activity due to duplication/amplification of the functional genes leads to inadequate drug plasma concentrations and undesirable side-effects. Since quinidine has shown to be a CYP2D6 inhibitor when given in low doses. It is thought that ultrarapid metabolizers should receive low doses of quinidine instead of higher doses of the drug (which further decrease the therapeutic effect of quinidine by increasing its metabolism and create toxic metabolites).","CYP2D*3:CYP2D*4:CYP2D*13 (ultrarapid metabolizers)"],
    ["Qingtao, H., et al.",2015,"Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635788/","Simvastatin","SLCO1B1","pre/post","Cardiology","Statin-related myopathy after taking simvastatin along with SLCO1B1 Gene T521C Polymorphism","SLCO1B1 (T521C)"],
    ["Maggo, S.D., et al.",2011,"Clinical implications of pharmacogenetic variation on the effects of statins.","https://www.ncbi.nlm.nih.gov/pubmed/21142270","Statin","CYP2D6:CYP3A4:CYP3A5:SLCO1B1:APO-E:CETP:HMG-CoA reductase","pre/post","Cardiology","Statin induced myopathy- Due to polymorphisms in CYP2D6, CYP3A4, CYP3A5, and also SLCO1B1. SLCO1B1 gene encodes an anion transport protein responsible for hepatic uptake of statins. The pharmacodynamic profile of statins is also affected by polymorphisms in APO-E, CETP, and the HMG-CoA reductase genes.","Variants in CYP2D6:CYP3A4:CYP3A5:SLCO1B1:APO-E:CETP:HMG-CoA reductase"],
    ["Asensi, V., et al.",2015,"Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=nevirapine+side+effect+pharmacogenetic","Stavudine","MTHFR:TS","pre/post","Infectious Disease","Increased risk of peripheral neuropathy and lipodystrophy in Spanish populations - due to Stavudine intake in patient with decreases TS expression and MTHFR polymorphism","TS:MTHFR1298(sn1801131)"],
    ["Asensi, V., et al.",2015,"Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.","https://www.ncbi.nlm.nih.gov/pubmed/?term=nevirapine+side+effect+pharmacogenetic","Tenofovir","ABCC2 ","pre/post","Infectious Disease","Renal proximal tubulopathy increased risk in French populations - due to ABCC2 (MRP2)1249G>A polymorphism and TeNofovir administration ","ABCC2 (MRP2)1249G>A"],
    ["Ghodke-Puranik, Y., et al. ",2014,"Valproic acid pathway: pharmacokinetics and pharmacodynamics","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696515/","Valproic Acid","POLG","pre/post","Neurology ","POLG polymorphisms are associated with mirgrane, epilepsy and Parkinson's disease; all of which are indications for the use of valproic acid. Additionally, functional POLG polymorphisms may increase the risk of liver failure in patients on VPA. ","POLG rs226957"]
];

function reorderColumns(input) {
    let output = [
        input[4],
        input[5],
        input[6],
        input[7],
        input[8],
        input[9],
        input[0],
        input[1],
        input[2],
        input[3],
    ];
    return output;
}




